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Resumo 
 
O carcinoma de células renais de células claras (CCRcc) é o subtipo mais frequente de 
CCR e está associado à perda ou inativação do gene VHL, que resulta, consequentemente, 
numa acumulação do fator de transcrição associado à hipoxia (HIF) em condições de 
normóxia. A acumulação deste fator potencia a transcrição de genes como o TGF-α e VEGF, 
que, em última instância, promovem a ativação de vias de sinalização proliferativas e 
angiogénicas centrais na progressão do CCRcc. O crescente conhecimento das vias de 
sinalização envolvidas no desenvolvimento e progressão do CCR permitiu, nos últimos anos, 
o desenvolvimento de novas terapias dirigidas a alvos moleculares específicos, com o intuito 
de melhorar as opções terapêuticas e a eficiência das mesmas. Um desses agentes é o 
bevacizumab, um inibidor de angiogénese, já usado no tratamento de doentes com CCR. 
Adicionalmente, o erlotinib, um inibidor do receptor de fator de crescimento epidérmico 
(EGFR), pode-se revelar uma potencial opção terapêutica no CCR dada a sobreexpressão do 
EGFR e sobreativação de vias associadas, verificadas neste modelo tumoral. Contudo, o 
desenvolvimento de resistência a terapias dirigidas é altamente frequente em CCR, o que 
enfatiza a importância de estudar mecanismos de escape à mesma. Os microRNAs 
(miRNAs), uma família de pequenas moléculas de RNA não codificantes, têm vindo a ser 
associados como importantes mediadores de resistência à terapia, visto que regulam a 
expressão genética e, consequentemente, diversos processos biológicos. A sobreexpressão 
do miRNA-21 tem vindo a ser associada com a resistência a terapias dirigidas ao EGFR, por 
ativação downstream da via PI3K/AKT.  A base deste mecanismo de resistência assenta no 
facto deste miRNA regular a transcrição de PTEN, uma fosfatase com atividade supressora 
tumoral que regula negativamente a atividade de AKT. O miRNA-210, um miRNA induzido 
pelo HIF, também poderá estar associado a mecanismos de resistência a terapias dirigidas 
ao EGFR, ao inibir a transcrição do MNT. O MNT é um importante regulador do ciclo 
celular e inibidor transcricional que compete com c-Myc pela ligação a Max. Visto que o c-
Myc é um fator de transcrição ativado por vias de sinalização associadas ao EGFR e 
importante impulsionador do avanço do ciclo celular quando ligado a Max, a desregulação 
desta interação poderá comprometer a resposta à terapia. 
O presente estudo in vitro foi realizado com recurso a duas linhas celulares: uma linha 
celular renal tumoral, FG-2, e uma linha celular renal tumoral resistente ao erlotinib, FG-2R, 
estabelecida no decorrer do presente estudo. Ensaios de viabilidade celular realizados na 
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linha celular FG-2 demonstraram a eficácia, in vitro, do erlotinib na inibição da proliferação 
celular (P= 0.006). Adicionalmente, verificou-se um efeito sinérgico do bevacizumab e 
erlotinib no tratamento, in vitro, da linha FG-2 (P= 0.007). A combinação do erlotinib com 
bevacizumab pode-se revelar eficaz, visto que afetam diferentes receptores, EGFR e 
VEGFR, mas os quais possuem vias de sinalização associadas comuns, como a PI3K/AKT 
e a MAPK/ERK. Contudo, este efeito no controlo da proliferação celular não foi previamente 
observado em ensaios clínicos que recorreram ao uso do erlotinib isolado ou em combinação 
com bevacizumab em doentes com CCR metastático. Posteriormente, avaliou-se os níveis 
intracelulares e extracelulares do miRNA-21 e do miRNA-210 nas linhas celulares em 
estudo. Os níveis intracelulares e extracelulares do miRNA-21 não apresentaram variações 
na linha FG-2R quando comparado com a linha FG-2 (P= 0.185 e P= 0.319, respetivamente). 
No entanto, o miRNA-210 apresentou-se sobreexpresso tanto a nível intracelular (P= 0.009) 
como a nível extracelular (P= 0.017) na linha FG-2R quando comparado com a linha FG-2. 
Concomitantemente com a sobreexpressão deste miRNA, os níveis de mRNA do MNT, um 
alvo do microRNA-210, encontraram-se diminuídos na linha FG-2R (P< 0.001). No presente 
estudo foi possível também demonstrar que simultaneamente com a sobreexpressão de 
miRNA-210 e subexpressão de MNT na linha FG-2R, verifica-se um aumento da interação 
c-Myc-Max na fase G1 do ciclo celular quando comparado com a linha FG-2 (1.76 ± 0.34). 
Em conclusão, o miRNA-210 poderá estar envolvido num mecanismo de resistência ao 
erlotinib por levar à diminuição da expressão de MNT e consequente aumento da interação 
de c-Myc-Max, promotora da entrada no ciclo celular e da proliferação celular. Porém, 
estudos adicionais serão necessários para validar o mecanismo de resistência proposto e para, 
possivelmente, vir a considerar este miRNA como indicador de resposta à terapia e até 
mesmo como um alvo terapêutico.  
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Abstract  
Clear cell renal cell carcinoma (ccRCC) is the most frequent hystologic subtype of RCC 
and is associated with loss or inactivation of the VHL gene, which leads to the accumulation 
of the hypoxia-associated transcription factor (HIF) in normoxic conditions. HIF triggers the 
transcription of different genes, such as TGF-α and VEGF, ultimately promoting the 
activation of crucial proliferative and angiogenic signaling pathways in ccRCC progression. 
In recent years, the discovery of relevant signalling pathways to RCC initiation and 
progression has allowed the development of molecular targeted drugs that take advantage of 
genetic addictions, dependences and vulnerabilities of cancer cells in order to maximize 
treatment effectiveness. Bevacizumab, an angiogenesis inhibitor, is an example of drugs 
developed to target more specifically cancer cells addictions and is already used in RCC 
patient´s treatment. Additionally, erlotinib, an epidermal growth factor receptor (EGFR) 
inhibitor, could represent an effective therapeutic option in RCC treatment since EGFR 
upregulation and EGFR-related signaling pathways overactivation is already described in 
this tumor model. Treatment resistance is highly frequent in RCC revealing the necessity of 
unveiling resistance mechanisms. MicroRNAs (miRNAs), a family of small non-coding 
RNAs, have been reported as mediators of treatment resistance mechanisms, since they 
regulate genetic expression and, consequently different cellular processes. MiRNA-21 
overexpression has been associated with EGFR-targeted therapies resistance, through 
PI3K/AKT downstream activation. The resistance mechanism is mainly through PTEN 
downregulation, a tumor-suppressing phosphatase that antagonizes the function of PI3K and 
negatively regulates AKT activity. MiRNA-210 could also be associated with EGFR 
targeted therapies resistance by downregulating MNT. MNT is an important cell cycle 
regulator due to its ability of competing with c-Myc for Max binding and, ultimately, due to 
its transcriptional inhibitor activity. Since c-myc is a transcription factor activated through 
EGFR-related signalling pathways and triggers cell cycle entry and progression when bound 
to Max, dysregulation of this interaction could lead to therapy resistance. 
The present study was performed using two different cell lines: a tumoral renal cell line, 
FG-2, and an erlotinib-resistant tumoral renal cell line, FG-2R, established during the 
development of this project. Viability studies performed in the FG-2 cell line demonstrated 
the erlotinib effectiveness in inhibiting cellular proliferation (P= 0.006). Additionally, a 
synergic effect of bevacizumab and erlotinib was also demonstrated when treating the FG-2 
cell line, in vitro (P= 0.007). The combination of erlotinib and bevacizumab may be 
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beneficial since they target different receptors, namely EGFR and VEGFR, that share 
downstream signaling pathways, such as PI3K/AKT and MAPK/ERK.The results obtained 
are not fully in line with the results of clinical trials performed in metastatic RCC patients, 
since the benefic effect of erlotinib alone or in combination with bevacizumab was hard to 
prove. Subsequently, miRNA-21 and miRNA-210 extracellular and intracellular levels were 
evaluated in the cell lines in study. On the one hand, intracellular and extracellular miRNA-
21 levels were not altered in the FG-2R cell line when compared to the FG-2 cell line (P= 
0.185 and P= 0.319, respectively). On the other hand, miRNA-210, which is regulated by 
HIF, presented higher intracellular (P= 0.009) and extracellular (P= 0.017) levels in the FG-
2R cell line when compared with the FG-2 cell line. Concomitantly with miRNA-210 
overexpression, MNT mRNA levels, a known target of this microRNA, were downregulated 
in the FG-2R cell line. In vitro studies performed demonstrated that simultaneously with 
miRNA-210 overexpression and MNT underexpression in the FG-2R cell line, c-Myc-Max 
interaction levels were higher in the G1 phase of the cell cycle when compared with the FG-
2 cell line (1.76 ± 0.34). 
In conclusion, miRNA-210 could mediate an erlotinib resistance mechanism by MNT 
downregulation and consequent increase in the c-Myc-Max interaction, promoting cell cycle 
entry and cell proliferation. However, additional studies are necessary to validate the 
proposed resistance mechanism and to, ultimately, consider this microRNA as a biomarker 
for treatment response and even as a therapeutic target. 
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1. Introduction 
 
1.1 Cancer 
 
Cancer has rose as an emergent public health problem, since it represents one of the 
leading causes of death worldwide [1, 2]. According to recent reports, an estimated 3,45 
million new cancer cases and 1,75 million cancer-related deaths occurred in 2012 in Europe. 
Breast cancer, colorectal cancer, prostate cancer and lung cancer cases represent almost half 
of cancer cases, in this continent [3]. These same types of cancer are also associated with the 
most cancer-related deaths in Europe in 2012, although stomach cancer and pancreatic 
cancer, 4th and 5th respectively, represent more deaths than prostate cancer [3]. Many risk 
factors promote carcinogenesis such as: tobacco use, alcohol use, unhealthy diet and physical 
inactivity but ageing is considered the biggest one [1, 2]. The average life expectancy of the 
world population is increasing which, not only, promotes the accumulation of genetic 
mutations on somatic cells but also is associated with a weakening of the immune system, 
leading, ultimately, to a more suitable environment to tumor development [1].  
Nowadays, cancer is considered a heterogeneous disease that develops trough 
interactions between environmental and genetic factors, involving the dysregulation of 
multiple pathways responsible for the fundamental cell processes, such as death, 
proliferation, differentiation and cell migration [1, 2]. Several evidences indicate that 
carcinogenesis is a multiphase process, which is associated with genetic and epigenetic 
modifications that promote a progressive transformation of normal cells into tumoral cells 
[4]. More in depth, carcinogenesis can be divided into three main phases: initiation, 
promotion and progression. Initiation is the first stage of tumor development where an 
irreversible genetic modification occurs through one or more point mutations, translocations, 
deletions, or even insertions in the DNA. Secondly, promotion is a reversible process that 
does not involve DNA structure modifications but is associated with a selective clonal 
expansion of initiated cells, producing a larger population of cells that are at risk of further 
genetic changes and malignant conversion. Ultimately, tumor progression can occur, 
characterized by the expression of a malignant phenotype and the tendency of malignant 
cells to acquire additional aggressive characteristics over time through further genetic and 
epigenetic modifications [5, 6]. During the carcinogenesis, genes that suffer modifications 
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and promote tumor initiation and progression are divided into three main groups: oncogenes, 
tumor suppressor genes and apoptosis-regulatory genes [7]. Proto-oncogenes are converted 
into oncogenes by gain-of-function mutations that may occur through three major 
mechanisms: point mutations, that result in a mutated and constitutively acting protein; gene 
amplification, that leads to protein overexpression; and chromosomal translocation, that 
alters transcription regulation of proto-oncogenes. These mutations act dominantly since a 
mutation in only one of the two alleles is sufficient for cancer induction. Tumor-suppressor 
genes commonly encode proteins related with cell proliferation inhibition. Only one copy of 
the tumor-suppressor genes is needed to maintain cell normal function and proliferation 
control, so loss of function of tumor-suppressor genes needs to occur in both alleles and most 
frequently involves point mutations in one allele and loss of the second allele by a deletion, 
recombinational event, or even chromosomal nondisjunction. Finally, apoptosis-regulatory 
genes can promote tumor development through both mechanisms [8]. This type of 
modifications are promoted through chemical, physical and biological carcinogens present 
in our daily life and also through endogenous factors [9].  
Until the year 2000 there was no proper definition and characterization of tumoral cells 
that could differentiate them from somatic cells. Thus, Hanahan and Weinberg proposed the 
Hallmarks of cancer for rationalizing the complexities of neoplastic disease and allowing 
the needed differentiation [4].  First, six Hallmarks were suggested: sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metastasis [4]. Since then more 
Hallmarks have been added to a more proper characterization of such a complex disease as 
cancer, such as evading immune destruction, metabolism dysregulation, tumor-promoting 
inflammation and also genetic instability and mutations, that promote tumor initiation and 
development [10]. The constant evolution in cancer scientific research resulted in the 
discovery of a large number of factors involved in tumor progression and also tumor cell 
vulnerabilities and dependencies, allowing the study and development of new therapeutic 
approaches. 
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1.2  Cancer Treatment 
 
Chemotherapy, along with surgery and radiotherapy, has been a crucial approach for 
cancer treatment. These different types of treatment can be used alone or in different 
combinations, and either simultaneously or sequentially. However, 
chemotherapy/radiotherapy-induced cell damage occurs preferentially but not exclusively in 
cancer cells, causing several side-effects [11]. For this reason, nowadays, a big effort is being 
made in order to improve a personalized medicine that focus on the discovery and development 
of molecular targeted drugs that take advantage of genetic addictions, dependences and 
vulnerabilities of cancer cells. This type of methodology would be more specific than previous 
described approaches by minimizing side effects on normal cells [12]. Additionally, different 
high-throughput technologies, still under development, like genome sequencing and various 
kinds of microarrays, will allow the knowledge of the genetic, epigenetic and proteomic 
background, from each individual and tumor, which ultimately will lead to a more personalized 
treatment [13]. 
The concept of targeting a pathogenic driver abnormality using a small molecule was 
first validated in 1988 by the successful treatment of patients with acute promyelocytic 
leukemia harboring translocations in the RARα (retinoic acid receptor) gene with all-trans 
retinoic acid [14]. Additionally, the use of imatinib, a BCR-ABL inhibitor, as a chronic 
myeloid leukemia treatment in 1996, marked the era of the design of small therapeutic 
molecules applied in cancer treatment [15]. The 8-year estimated overall survival rate for 
patients with this malignancy, characterized by the BCR-ABL translocation, has improved 
from 42-65% in 1983-2000 to 87% since 2001, mainly due to the use of imatinib as initial 
therapy [16]. 
Even with all the developments and improvements in cancer therapy, resistance to 
treatment still exists. Therapy failure is often due to development of drug resistance that may 
be inherent in a subpopulation of heterogeneous cancer cells or acquired subsequent to 
treatment [11]. A well characterized resistance mechanism is related with the activity of ABC 
transporters. ABC transporters are transmembrane proteins responsible for the transport of a 
wide variety of substrates across cellular membranes, including hydrophobic drugs and 
antibiotic [17, 18]. Overexpression of these proteins can be associated with reduced drug 
uptake, increased drug efflux and lead to lower drug efficacy and possibly to acquire drug 
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resistance due to low drug levels in the cytoplasm [18]. The major members of the ABC 
transporters associated with multidrug resistance in cancer cells are ABCB1/MDR1, ABCCs 
and ABCG2 [19]. Although, several have been identified as transporters of cancer 
chemotherapeutics agents, acquired chemotherapy drug resistance can occur at many levels, 
modulated either by genetic or epigenetic factors. In fact, recent data demonstrate that the 
activity of certain microRNAs (miRNAs) might be altered in order to achieve resistance to 
chemotherapy [12]. In the same line of thought, miRNAs can be as well linked to acquired 
resistance in molecular targeted therapy in several malignancy treatments.  
 
1.3 MicroRNAs and Therapy Resistance  
 
MiRNAs are a class of non-coding RNAs (19-25 nucleotides in length) that control 
gene expression by either degrading or blocking translation of mRNAs a process that 
depends on the miRNA-mRNA target degree of complementarity [20]. MiRNA biogenesis 
initiates at the nucleus with the transcription of a primary RNA, the pri-miRNA, by RNA 
polymerase II [21]. Afterwards, pri-miRNA is processed by Drosha, an RNase III 
endonuclease, alongside with cofactor DGCR8, creating a pre-miRNA [22]. The pre-
miRNA is exported to the cytoplasm by the nuclear export protein XPO5, where it is further 
processed by DICER, leading to the production of a mature 22 nucleotide-stranded molecule 
[21]. The mature miRNA enters the RNA-induced silencing complex (RISC), whose main 
components are TRBP (Tar RNA-binding protein), AGO1-4 (Argonaute 1-4), GEMIN3 
(Gem-associated protein 3) and GEMIN4 (Gem-associated protein 4) becoming, ultimately, 
a functional miRNA [23]. This complex binds to the target mRNA at 3´UTR region by 
complementarity leading to gene silencing (Figure 1) [24].                                   
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MiRNA expression is dynamic, since a miRNA can regulate up to 100 different 
mRNAs and that more than 10.000 mRNAs appear to be directly regulated by miRNAs [25]. 
Thus, changes in the miRNA processing and expression patterns could be associated with 
different pathologies, including cancer, suggesting that miRNAs are involved in many 
cellular function disorders, which could ultimately lead to carcinogenesis [26]. 
After the discovery of miRNA-15a and miRNA-16-1 as the first miRNAs with tumor 
suppressor functions in chronic lymphocytic leukemia in 2002, several others miRNAs have 
been described as mediators of cancer related-signaling pathways, regulating proliferation, 
apoptosis, angiogenesis and even epithelial-mesenchymal transition (EMT), a key step for 
the metastatic process [27, 28]. Depending on mRNA targets and their impact on different 
biological processes, miRNAs can be described to act as oncogenes - oncomiRNAs, tumor 
suppressors – miRNAs tumor suppressors or even modulators of cancer stem cells and 
metastasis formation. OncomiRNAs are, usually, overexpressed in cancer since they are 
known to downregulate tumor suppressor genes and tumor suppressor miRNAs are 
responsible for downregulating oncogenes, so are mostly under-expressed in malign 
neoplasms [29, 30]. However, this dichotomous approach may have its limitations. For 
Figure 1- MicroRNAs biogenesis and regulation mechanisms (Adapted from Dias, F., et al. [32]). 
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example, miRNA-17 is associated, in B-cell lymphoma, with faster tumor development, 
while it can suppress cancer growth by downregulating AIB1 expression in breast cancer 
[31, 32]. Therefore, it is important to take into account that a microRNA may act as an 
oncomiRNA or a tumor suppressor miRNA depending on the type of tissue. 
One of the most interesting features of miRNAs is that they are able to circulate in 
the majority of biological fluids [33]. Circulating miRNAs are highly stable even when 
submitted to severe conditions, such as boiling, very low or high pH, extended storage, and 
several freeze-thaw cycles, conditions that would normally degrade most RNAs [34]. They 
also exhibit protection from RNase activity due to the fact that most microRNAs circulate 
inside of exosomes in the different biological fluids [35]. Exosomes are membrane-bound 
vesicles of 40–100 nm in diameter released from most cell types, including cancer cells, 
enriched in cholesterol, sphingomyelin and ceramide as well as lipid raft associated proteins 
which allows them to be highly stable in circulation [36-38]. Due to its features, this type of 
extracellular vesicles has the ability of horizontal cargo transfer interacting with neighboring 
or distant cells [39]. In cancer, tumor-derived exosomes containing miRNAs can modulate 
biological processes inside of recipient cells, in a systemic manner [35].  
Regarding the miRNAs role in cell communication and cellular processes such as 
proliferation, apoptosis or angiogenesis, it is important to take into account the effect that 
changes in miRNA levels may have in treatment response, since targeted therapies are used 
for specific proteins and signal pathways related with this biological processes [27, 28]. 
In fact, many studies have been identifying miRNAs as molecules involved in 
acquired resistance to targeted therapies in different tumor models [40]. For example, studies 
in non-small cell lung cancer (NSCLC) performed by Shen et al. stated that miRNA-21 
correlated with PTEN levels, one of its targets, modulates gefitinib resistance [41, 42]. A 
significantly higher expression of miRNA-21 and a reduction in PTEN protein levels was 
found when comparing tumor tissues with adjacent normal tissues of patients with NSCLC. 
It was also described that patients with the highest levels of expression of miRNA-21 and 
lowest protein levels of PTEN exhibited poor tyrosine kinase inhibitors (TKI) clinical 
response and shorter overall survival [42]. Simultaneously, in vitro studies were performed 
using a PC-9 TKI sensitive cell line and a gefitinib-resistant cell line, PC-9/GR, in order to 
test the effect of high miRNA-21/low PTEN expression on modulation of TKI sensitivity. 
MiRNA-21 was upregulated concomitantly to downregulation of PTEN in PC-9/GR cells, 
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which leads to activation of AKT and ERK pathways and, ultimately, low sensitivity to 
gefitinib [42]. Ragusa and co-workers also demonstrated that miRNAs might be involved in 
targeted therapy acquired resistance in colorectal cancer (CRC). They performed an 
expression profile of a large number of miRNAs in two human colorectal cancer cell lines, 
one cetuximab sensitive (Caco-2) and other cetuximab resistant (HCT-116). MiRNAs let-7b 
and let-7e were downregulated in the cetuximab resistant cell line, HCT-116, in which 
signaling downstream of KRAS remains activated. Let-7 family members are known to 
target KRAS, so their downregulation could be a mechanism that contributes to cetuximab 
resistance [43] (Table 1). Regarding renal cell carcinoma (RCC), our tumor model of study, 
studies have not yet been performed relating microRNAs and targeted therapies resistance 
but this theme represents an interesting field of study since therapy resistance is a big issue 
in this type of cancer [44]. 
 
 
 
 
Figure 2 - Summary of the miRNAs involved in the acquired resistance to ErbB family targeted therapies by 
cancer type. 
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1.4 Renal Cell Carcinoma  
 
Kidney cancer represents a heterogeneous group of renal carcinomas with different 
molecular and histological patterns and a wide range of clinical characteristics and treatment 
responses [45]. 
The most common kidney solid cancer in adults is the renal cell carcinoma (RCC) 
accounting for approximately 90% of kidney neoplasms and representing 2-3% of all cancers 
worldwide [46, 47]. There is a 1.5:1 predominance of new RCC cases diagnosed in men over 
women, with a incidence peak between the age of 60 and 70 years old [47]. In Europe, RCC 
represents the 9th most incident adult malignancy (84400 new cases and 34700 kidney 
cancer-related deaths in 2012), being Portugal one of the European countries with the lowest 
incidence rates [3, 46, 47]. Incidence and mortality rates of RCC show a geographic 
variation: the highest incidence rates are observed in Northern America, Western Europe 
and Australia, whereas the lowest are observed in India, China and Africa. The highest 
mortality rates are registered in the European continent, mainly in the Central and Eastern 
countries, followed by the western and southern regions (Figure 2) [46, 47].     
 
Figure 3 - Kidney cancer mortality rates per 100 000 habitants, in both genres (Adapted from GLOBOCAN 
2012, IARC). 
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The geographic disparity observed in RCC incidence rates worldwide can be 
attributed to differences in diagnosis frequency, access to health care, genetic inheritance 
and prevalence of certain lifestyle habits and/or environmental risk factors. Different 
epidemiological studies revealed that smoking habits, obesity, hypertension and also 
acquired cystic disease and family history of RCC seem to be involved in the etiology and 
development of RCC [46, 48-51]. 
 Currently, most RCCs are detected accidentally as a consequence of imaging 
examinations, such as computed tomography and magnetic resonance imaging [52]. This 
occurs due to the fact that many renal masses remain asymptomatic and nonpalpable until 
the late stages of the disease [52]. In case of accidentally diagnosis, the prognosis is good 
and further exams, such as biopsies and aspiration cytology, are needed to confirm the tumor 
neoplastic nature. Clinical symptoms, such as flank pain, gross hematuria, palpable 
abdominal mass, and paraneoplastic syndromes, only appear when the tumor presents a 
larger diameter, which can be associated with a worse prognosis [47, 53, 54]. Regarding this 
facts and the nonexistence of a standard screening test, one-third of patients are diagnosed 
with local invasive disease or metastatic disease [52].  
The classification system most widely accepted for histologic grading of RCC is the 
Fuhrman nuclear grade, grouping the RCC cases into four main groups [53, 54]. Fuhrman 
nuclear grades 1-2 are associated with tumors in initial stages of development and better 
prognosis and 3-4 with worst prognosis due to a greater tumor malignancy and 
aggressiveness. [53, 54]. 
Therapeutics options in RCC depend on many factors such as: tumor size and 
location, local or distant invasiveness, renal function and others [47]. In initial stages of RCC 
development, surgical intervention is the primary treatment used. However, surgery does not 
represent a good therapeutic option, when used alone, in patients with metastatic disease [55, 
56]. Due to the fact that RCC is highly resistant to cytotoxic chemotherapy and radiotherapy, 
until recently treatment options for patients with metastatic RCC (mRCC) were extremely 
limited [57, 58]. Cytokine therapies such as interleukin-2 and interferon-alpha were one of 
the first systemic treatment options in mRCC but they proved to be ineffective since only a 
small percentage of the patients showed benefit in long-term disease-free survival [59, 60]. 
More recently, due to the discovery of which molecular pathways are constitutively activated 
and are important for RCC development and progression, targeted agents such as receptor 
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tyrosine kinase inhibitors (TKIs), vascular endothelial growth factor (VEGF) antibodies, and 
mammalian target of rampamycin inhibitors (mTORs) started to represent a fundamental 
approach in mRCC treatment [52, 56, 61]. Although mRCC patient’s outcome has improved, 
targeted therapies acquired resistance still occurs after a median of 5-11 months due to 
genetic and epigenetic changes but mainly through downstream activation of the signaling 
pathway targeted therapy site [40, 44, 62]. 
 
1.5 Clear Cell Renal Cell Carcinoma oncobiology and its relation with 
microRNAs 
 
According to the ISUP Vancouver Modification of World Health Organization 
(WHO), there are more than twenty-four histologic subtypes of RCC being the clear cell, 
papillary (type I and II) and chromophobe the most frequent subtypes [63-65]. The clear cell 
renal cell carcinoma (ccRCC) is considered the most aggressive subtype [63]. ccRCC is 
associated with the von Hippel-Lindau syndrome, a hereditary condition, or with the loss of 
function of the tumor suppressor gene, VHL, in sporadic cancer cases [66, 67]. Usually 
inactivation of the VHL gene present in the chromosome 3p25.3 occurs through a mutation 
in one of the alleles and a deletion on the second one [66]. In fact, in 90% of the ccRCC 
cases occurs a total loss of the chromosome 3 short arm [66]. In normoxic conditions, the 
protein encoded by the VHL gene serves as a recognition site for the regulatory subunits of 
HIF, targeting them with ubiquitin to proteasome degradation. With the loss of VHL in 
ccRCC, the degradation of HIF stops and leads to its accumulation in the cytoplasm and 
further migration to the nucleus where it binds to hypoxia-related genes, leading to a hypoxic 
response from the cell in normoxic conditions [68]. Some of the genes activated by HIF are 
associated with blood vessels development (Erithropoietin - EPO and Vascular endothelial 
growth factor - VEGF), proliferation (Platelet derived growth factor beta – PDGF-β and 
Transforming growth factor alpha - TGF-α), glucose metabolism (Glucose transporter 1 - 
GLUT 1) and metastization (Chemokine (C-X-C motif) receptor 4 - CXCR-4) (Figure 3) 
[69, 70].  
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Figure 4- pVHL pathway under hypoxic conditions: the loss of VHL leads to the accumulation of HIF-α in the 
nucleous and consequene binding to transcription factors, which triggers a hypoxic response from the cell 
(Adapted from Dias, F., et al. [42]).  
 
One of the activated genes is the transforming growth factor α (TGF-α), which is 
involved in the induction of cellular proliferation by activating the epidermal growth factor 
receptor (EGFR) [71]. The EGFR activates several signaling pathways such as MAPK/ERK 
and PI3K/AKT which in turn modulate genetic transcription, stimulating cellular 
proliferation, migration, invasion, angiogenesis and apoptosis [72-75]. EGFR belongs to the 
ErbB/HER family of tyrosine kinase receptors and is often dysregulated in cancer [76]. It is 
overexpressed in, approximately, 30% of primary tumors of several cancer types and has 
been associated with advanced disease, poor prognosis, limited overall survival and therapy 
response [77]. In RCC, multiple analysis has shown an overexpression of EGFR ranging 
from 40–80% [78-80]. This may occur due to the fact that pVHL is also responsible for 
activated EGFR downregulation by promoting efficient lysosomal degradation of the 
receptor, an event that during the RCC development could be compromised leading to an 
increase of EGFR [71]. Zhou and co-workers performed an in vitro study in ccRCC 
describing that EGFR half-life was approximately 1 hour in VHL-expressing ccRCC cells 
but approximately 3 hours in mock ccRCC cells and that both phospo-AKT and the phospo-
ERK signals lasted longer in mock ccRCC cells when stimulated with epidermal growth 
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factor (EGF) [71]. Recently, Shen and colleagues demonstrated that EGFR is upregulated 
during tumor progression and specifically enriched in hypoxic tumor areas [81]. They also 
desmonstrated that EGFR suppresses the maturation of specific tumour-suppressor-like 
miRNAs in response to hypoxic stress through phosphorylation of argonaute 2 (AGO2) at 
Tyrosine 393 [81]. Taken together, this results demonstrate the importance of studying the 
VHL-EGFR pathway to further understanding of ccRCC molecular biology, and the 
involvement of this pathway in ccRCC tumor progression.  
In recent years, the increasing knowledge of the pathways involved in ccRCC has 
allowed the development of new targeted therapies. The identification of alterations in VHL 
gene in ccRCC led to the development of targeted therapies such as sunitinib and sorafenib 
- tyrosine kinase inhibitors, as well as pazopanib (angiogenesis inhibitor) [70, 82]. 
Considering the facts stated before, erlotinib, an EGFR tyrosine kinase domain inhibitor, 
could have a benefic impact in ccRCC treatment inhibiting EGFR-related pathways since a 
subset of patients (~25%) do not seem to experience any clinical benefit from targeted 
therapies used nowadays and even patients that initially respond to therapy later develop 
resistance and disease progression occurs [44]. In fact, phase I and phase II clinical trials 
have already been performed in metastatic ccRCC patients using erlotinib alone or 
simultaneously with bevacizumab (angiogenesis inhibitor) but the positive impact of EGFR 
blockade in metastatic ccRCC patients was hard to prove [83, 84]. These “failures” of 
targeted therapies show us the necessity of further investigating the mechanisms involved in 
innate or acquired resistance and also the molecular events crucial for the progression of this 
type of cancer which, ultimately, would allow the development of new effective targeted 
therapies. 
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As stated before, miRNAs may be way to unveil acquired resistance mechanisms and 
ultimately be seen as therapeutic options [85]. In ccRCC, as a consequence of VHL loss and 
EGFR activation some miRNAs present altered expression patterns such as miRNA-21 and 
miRNA-210 (Figure 4) [30]. 
 
 
MiRNA-21 has been described as an oncomicroRNA with an important role in cancer 
development [86, 87]. In a variety of cancer cell lines, overexpression of miR-21 was able 
to increase cell proliferation, migration, invasion and survival, while its suppression could 
induce apoptosis and repress cell proliferation and invasion capacity [88]. MiRNA-21 
transcription can be induced by EGFR-related AP1 and NF-kB transcription factors and 
MAPK/ERK signaling pathway [89, 90]. In RCC, microRNA-21 was indicated as a potential 
diagnosis and prognosis biomarker since it is overexpressed in tumor samples when 
compared with normal kidney tissue and higher miRNA-21 levels were associated with 
higher stage and grade of RCC tumors [91]. Since one of miRNA-21 targets is PTEN, a 
tumor-suppressing phosphatase that antagonizes the function of PI3K and negatively 
regulates AKT activity, its overexpression has been associated with ErBb family targeted 
therapies acquired resistance in lung, breast and gastric cancer studies [42, 92, 93]. High 
Figure 5 - Link between the VHL and EGFR pathways and microRNAs involved (Adapted from Dias, F., et 
al. [32]). 
30 
 
levels of miRNA-21 leads to a PTEN downregulation and consequently to an overactivation 
of AKT signaling pathway [93].  
MiRNA-210 is a miRNA that is regulated by HIF-1α [94]. HIF-1α accumulation in 
the cell is a key event in RCC due to VHL loss, therefore higher levels of this miRNA are 
expected in RCC patients [95]. In fact, Valera and coworkers described an overexpression 
of miRNA-210 in RCC patients and demonstrated that increased expression levels of miR-
210 are associated with higher Fuhrman nuclear grade tumors and tumors with lymph node 
metastasis [95]. Some reports indicate that miRNA-210 may control c-Myc activity by 
downregulating MNT expression, a c-Myc antagonist [96-98]. On the one hand, c-Myc 
promotes cell cycle entry and when dysregulated contributes to tumor formation due to its 
bHLHZip domain, which mediates heterodimerization with Max and DNA binding [99]. The 
Myc–Max heterodimer is able to bind DNA at the E-box consensus sequence CANNTG and 
activate transcription [100]. On the other hand, MNT is also a Max interacting protein but 
with a transcriptional repressor activity, antagonizing Myc-dependent cell proliferation 
[101]. MNT seems to have an important role in cell cycle entry, since cells lacking MNT 
exhibited an accelerated G0 to S-phase transition which, ultimately, could lead to 
tumorigenesis [102]. Since c-Myc is a transcription factor highly activated through EGFR-
related pathways, higher levels of miRNA-210 could represent a resistance mechanism to 
EGFR targeted therapies through MNT downregulation and loss of cell cycle entry control 
due to a higher Max availability to interact with c-Myc [103]. However, to the best of our 
knowledge, miRNA-210 has not yet been associated with acquired resistance to EGFR 
targeted therapies. 
More than one miRNA may be involved in acquired resistance mechanisms for the 
same drug and in the same tumor model. With this being said, it is more likely that an 
acquired resistance to a targeted therapy would be mediated by a network of miRNAs rather 
than a single one, targeting multiple sites of different pathways. However, it is important to 
unveil miRNA-mediated resistance mechanisms for better understanding and prediction of 
treatment response, allowing a more personalized and effective treatment. 
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2. Objetives 
 
2.1 Main objective 
 
Characterization of a microRNA mediated resistance mechanism to erlotinib in renal cell 
carcinoma. 
 
2.2 Specific objectives 
 
 Evaluation of erlotinib and bevacizumab cellular toxicity in a renal cell carcinoma 
cell line. 
 
 Establishment of an erlotinib-resistant renal cell carcinoma cell line. 
 
 In vitro quantification of microRNA-21 and microRNA-210 intracellular and 
extracellular levels in a renal cell carcinoma cell line, FG-2, versus an erlotinib-
resistant renal cell carcinoma cell line, FG-2R. 
 
 In vitro quantification of mRNA MNT levels and its correlation with the microRNAs 
levels, previous mentioned, in a renal cell carcinoma cell line, FG-2, versus an 
erlotinib-resistant renal cell carcinoma cell line, FG-2R. 
 
 
 Determination of the functional relationship between microRNA-210 and MNT. 
 
 In vitro evaluation of the microRNA-210 mediated resistance mechanism.  
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3. Matherial and Methods 
 
3.1 Cell line characterization  
 
For the present study was used one cell line, FG-2, described as a metastatic RCC 
cell line and kindly provided by Dr. Klaas Kok from Groningen University, Netherlands 
(Figure 6).  
 
 
 
 
 
 
 
To confirm the tumoral phenotype of the cell line in study, it was performed a 
Fluorescence in situ Hybridization (FISH) technique to detect the absence of the VHL gene. 
It was used a specific probe for the centromere of the short arm of chromosome 3 and a 
specific probe for the VHL gene. As expected there was loss of the VHL gene in the FG-2 
cell line (Figure 7). 
 
 
 
 
Figure 6 - Microscope image (10x) of the FG-2 cell line. 
 
Figure 7 - Microscopic image of the chromosome 3 centromeres and VHL genes present in the FG-2 cell line. 
(Red dye - chromosome 3 centromere; green dye – VHL gene). Images provided by Dr. Joana Vieira from the 
IPO-Porto Genetic Department.    
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3.2 Establishment of an erlotinib-resistant renal cell carcinoma cell line 
and cell culture 
   
Initially a cryopreserved vial of the FG-2 cell line was thawed. The FG-2 cell line 
was maintained in RPMI 1640 (1X) medium (Gibco®), supplemented with 10% of FBS 
(Fetal Bovine Serum) (Gibco®), and 1% of Pen-Strep (Gibco®). An erlotinib-resistant 
subline (FG-2R) was generated upon exposure of the FG-2 cell line to crescent 
concentrations of erlotinib. Specifically, 15 days exposure to erlotinib at 3µM, 15 days 
exposure to erlotinib at 5µM and 2 months exposure to erlotinib at 10µM. Cell counting 
using a Neubauer chamber and Tripan-Blue dye (Gibco®) was performed, in the presence 
and absence of erlotinib, at the end of the erlotinib-resistant renal cell carcinoma cell line 
establishment to confirm the resistance to the drug. Then, both cell lines were maintained in 
a 5% CO2 incubator at 37ºC during all phases of the study.  
When the desired confluence was achieved (80-90%) the medium, in which the cells 
were being cultured, was collected for miRNA extraction and the cells were trypsinized, 
using 0.05 % trypsin-EDTA (1×) (Gibco®) and counted using a Neubauer chamber and 
Tripan-Blue dye (Gibco®). After counting, approximately 1.5 million cells were centrifuged 
to form a pellet for either miRNA or mRNA extraction and the remaining cells were kept in 
culture.  
This procedure was repeated until ten cell and medium microRNA extractions and 
ten cell mRNA extractions were performed for the FG-2 cell line. Taking in consideration 
the FG-2R cell line, this procedure was performed at the end of the 15 days exposure to 
erlotinib at 5µM, at the end of 1 month exposure to erlotinib at 10µM and at the end of the 
establishment of the erlotinib-resistant renal cell carcinoma cell line. At least three cell and 
medium microRNA extractions and three mRNA extractions were performed at each phase 
mentioned.  
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3.3 MicroRNA and mRNA extraction and cDNA synthesis 
 
MicroRNA extraction from the cells and respective medium was performed using the 
GRS microRNA kit (Grisp®) according to manufacture instructions. After isolation, 
NanoDrop® ND-1000 spectrophotometer was used to determine miRNA concentration and 
purity by measuring absorbance at 260 and 280 nm. The miRNA samples were then used as 
templates for cDNA synthesis using a Taqman®MicroRNA Reverse Transcription kit 
(Applied Biosystems®) and sequence-specific primers for miRNA-21, miRNA-210 and 
functioning as endogenous controls, for RNU-6B e RNU-48. The mRNA extraction was 
performed using the GeneJET™ RNA purification kit (Thermo Scientific®) according to 
manufacture instructions. After isolation, mRNA concentration and purity were measured at 
260 and 280 nm using the NanoDrop® ND-1000 spectrophotometer. The mRNA samples 
were then used as templates for cDNA synthesis using High-Capacity RNA-to-cDNA Kit 
(Applied Biosystems®).  
 
3.4 Real-time PCR relative quantification 
 
The miRNA and mRNA expression was analyzed by quantitative real-time PCR. The 
reactions were carried out on a StepOneTMqPCR Real-Time PCR machine, containing 1X 
Master mix (Applied Biosystems®), with 1X probes (TaqMan® microRNA Expression 
Assays, miR-21:TM000397, miR-210:TM000512, TaqMan® microRNA Control Assays, 
RNU-6B: TM-001093, RNU-48: TM-001006 and TaqMan® Gene Expression Assays, MNT: 
Hs00232758, c-Myc: Hs00153408, B2M: Hs00187842, Applied Biosystems®) and a cDNA 
sample.  RNU-6B and RNU-48 were used and quantified to determine which one had the 
most constant expression levels in the microRNA tested samples to normalize results and 
function as endogenous control. B2M was used as an endogenous control to mRNA tested 
samples. Data analysis was performed using StepOneTM Sofware v2.2 (Applied Biosystems®).  
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3.5 Bevacizumab and erlotinib cellular toxicity test 
 
In this study, 100000 cells of the FG-2 cell line were cultured in 12-well plate. After 
24h, cells were administered with DMSO (erlotinib dilution solution), NaCl 0,9% 
(bevacizumab dilution solution), DMSO and NaCl 0,9%, erlotinib at a final concentration of 
10µM, bevacizumab at a final concentration of 150 µg/mL or erlotinib at a final 
concentration of 10µM and bevacizumab at a final concentration of 150 µg/mL. Each 
condition was performed in triplicate. After 72h of administration, cells were trypsinizated 
and counted using, once again, a Neubauer chamber and Tripan-Blue dye (Gibco®). This 
experience was performed in duplicate.  
Optimal concentrations of erlotinib and bevacizumab were determined prior to this 
study in similar fashion, using crescent concentrations. 
 
3.6 Analysis of microRNA-210 and MNT functional relationship 
 
On the present study, 150000 cells of the FG-2 cell line were cultured in 24-well 
plate and reversely transfected with a scrambled sequence (kindly provided by Dr. Germana 
Zaccagnini) or with microRNA-210 mirVana® miRNA inhibitor (MH10516, Applied 
Biosystems®), using ScreenFect A reagent (InCella®) according to manufacture instructions.  
After 24h, cells were trypsinizated and microRNA and mRNA extraction was performed for 
each condition for further analysis by real-time PCR of microRNA-210, RNU-6B, MNT and 
B2M levels. This experience was performed in triplicate. 
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3.7 FG-2 cell line conditioning  
 
Two different experiments using FG-2R conditioned medium were performed in the 
FG-2 cell line. First, 550000 cells of the FG-2 cell line were cultured in 6-well plate. After 
24h, growth medium was removed and either 5mL of FG-2R conditioned medium or, as an 
experiment control, 5mL of FG-2 conditioned medium was added. Both conditions were 
performed in duplicate. After 8h, cells were trypsinizated and microRNA extraction was 
performed for further analysis of microRNA-21, microRNA-210 and RNU-6B levels by 
real-time PCR, as previously mentioned. Secondly, an experiment was performed to test if 
the FG-2 cell line conditioning was time-dependent. For that matter, 500000 cells of the FG-
2 cell line were cultured in 6-well plate with FG-2R conditioned medium in a ratio of 1:1 
with FG-2 growth medium during 2 days, 1 week or 2 weeks. Each condition was performed 
in duplicate. Cells microRNA extraction and quantification of microRNA-21, microRNA-
210 and RNU-6B levels by real-time PCR were performed at each exposure time of the 
study. 
 
3.8 Erlotinib response of the FG-2R cell line transfected with a 
microRNA-210 inhibitor  
 
For this study, 70000 cells of the FG-2R cell line were cultured in 24-well plate with 
growth medium supplemented with erlotinib at a final concentration of 10µM and reversely 
transfected with a scrambled sequence (kindly provided by Dr. Germana Zaccagnini) or with 
microRNA-210 mirVana® miRNA inhibitor (MH10516, Applied Biosystems®), using 
ScreenFect A reagent (InCella®) according to manufacturer recommendations. After 72h, 
erlotinib response was evaluated by viable cell counting using a Neubauer chamber and 
Tripan-Blue dye (Gibco®) after trypsinization. This experiment was performed in triplicate. 
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3.9 Co-Immunoprecipitation 
 
Co-immunoprecipitation was performed to analyze protein-protein interaction 
between c-Myc and Max in G1 phase of the cell cycle in FG-2, FG-2R and FG-2R 
transfected with microRNA-210 mirVana® miRNA inhibitor (MH10516, Applied 
Biosystems®). First, 750000 cells of the FG-2R cell line were cultured in 6-well plate and 
reversely transfected with microRNA-210 mirVana® miRNA inhibitor (MH10516, Applied 
Biosystems®), using ScreenFect A reagent (InCella®) according to manufacturer 
recommendations, for c-Myc and Max interaction analysis after 72h. Simultaneously, FG-2 
and FG-2R cell lines were grown to confluence in a T25. After 24h of FG-2R transfection, 
in all conditions growth medium was switched from medium containing 10% FBS to 
medium containing 0.1% FBS. Cells were maintained in 0.1% FBS for 2–3 days before 
stimulating with medium containing 10% FBS for 6h, which allowed G1 phase entry. After 
this period of time, cells were washed with PBS (InvitrogenTM) and cell lysis was performed 
using a mix of proteases inhibitor and co-immunoprecipitation buffer in a ratio of 1:200. 
Protein extracts were stored at -20ºC. After protein quantification by bicinchoninic acid 
method (BCATM Protein Assay, Pierce), 30 μg of total protein from each condition was 
stored at -20ºC for western blot analysis and 150 μg of total protein of each condition was 
incubated overnight at 4ºC with 4 μg of anti-Max (C-17, Santa Cruz Biotechnology®) or with 
4 μg of mouse IgGs, acting as control. After overnight incubation, samples were 
centrifugated 10 minutes at 13000 rpm. Subsequently, 10 μL of magnetic beads were added 
to each condition and incubated during 1h while in rotation. After this step, magnetic beads 
were washed five times with co-immunoprecipitation buffer and then GLB (1X) and DTT, 
at a final concentration of 0,1M, was added to the beads for protein elution. Simultaneously, 
these two reagents were also added to the 30 μg of total protein stored at -20ºC for western 
blot analysis from each condition (FG-2, FG-2R and FG-2R transfected with microRNA-
210 inhibitor). Samples from each condition were heated for 10 minutes at 50ºC and then 
magnetic beads were removed from solution. Afterwards, samples were loaded into a 14% 
SDS-PAGE polyacrylamide gel and running conditions were 200 V and 30 mAp. Once the 
dye front ran off the bottom of the gel, the gel was removed and proteins were transferred to 
a nitrocellulose membrane using Trans-Blot® TurboTM Kit (BIO-RAD®) and Trans-Blot® 
TurboTM Transfer System (BIO-RAD®), according to manufacturer recommendations. After 
the transfer was completed, a ponceau solution (1X) was added to the nitrocellulose 
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membrane for co-immunoprecipitation and transfer efficiency control. Subsequently, the 
nitrocellulose membrane was divided into two according to the molecular weight of the 
proteins in study and ponceau solution was removed. Then, the membranes were incubated 
and blocked during 1 hour in 5% skim milk in TBS-TritonX 0,2%. After this step, 
membranes were incubated overnight with anti-c-Myc primary antibody (9E10, Santa Cruz 
Biotechnology®) on a 1:100 dilutions in 2% skim milk in TBS-TritonX 0,2% or with anti-
Max primary antibody (C-17, Santa Cruz Biotechnology®) on a 1:200 dilutions in 2% skim 
milk in TBS-TritonX 0,2%. On the next day, membranes were washed with TBS-TritonX 
0,2% and incubated during 1 hour with the respective secondary antibody on a 1:10 000 
dilutions in 2% skim milk in TBS-TritonX 0,2%. Finally, membranes were washed in TBS-
TritonX 0,2% and incubated with ClarityTM Western ECL Substrate (BIO-RAD®), according 
to manufacturer recommendations, for visualization on a ChemiDoc machine using 
ImageLab (BIO-RAD®). 
 
3.10 Statistical Analysis  
 
      Statistical analysis was performed using IBM®SPSS®Statistics for Windows 
(Version 20.0). Livak method (2-ΔΔCt) and t´ student test was used to evaluate the differences 
in the expression levels of the normalized miRNAs and mRNAs. Western blot analysis was 
performed using ImageLab software (BIO-RAD®).  
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4. Results 
 
4.1 Bevacizumab and erlotinib cellular toxicity test 
 
In vitro studies were performed in the FG-2 cell line to determine erlotinib and 
bevacizumab cellular toxicity, separately and simultaneously. In figures 8 and 9, are 
represented the number of viable and non-viable cells obtained in response to different 
concentrations of bevacizumab and erlotinib. Moreover, in figure 10 we can observe the 
effect of bevacizumab and erlotinib, when used simultaneously, in cell viability. Regarding 
the results acquired for bevacizumab exposure of the FG-2 cell line, no differences were 
observed in cell viability when comparing the condition control, where cells were exposed 
to NaCl 0,9%, and any of other conditions where the FG-2 cell line was exposed to different 
bevacizumab concentrations (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Number of viable and non-viable FG-2 cells after 72h exposure to different bevacizumab 
concentrations (Mean ± SEM). 
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Figure 10 - Number of viable and non-viable FG-2 cells after 72h exposure to bevacizumab and erlotinib, 
separately or simultaneously (Mean ± SEM; *P≤0.050). 
 
According to the results obtained for erlotinib exposure of the FG-2 cell line, there were 
statistical significant differences in cell viability between the control condition, where cells 
were exposed to DMSO, and the 10µM erlotinib exposure condition (P= 0.006) (Figure 9). 
Since this condition led to, approximately, the death of 50% of the FG-2 cells we considered 
as our comparison condition.  
 
 
 
 
 
 
Additionally, the FG-2 cell line was also exposed to bevacizumab and erlotinib 
simultaneously. Statistical significant differences in cell viability were found between the 
10µM erlotinib exposure condition and the 10µM erlotinib + 150µg/mL bevacizumab 
exposure condition (P= 0.007), revealing a synergic effect of these two drugs (Figure 10). 
  
 
 
 
 
 
´ 
 
 
Figure 9 - Number of viable and non-viable FG-2 cells after 72h exposure to different erlotinib concentrations 
(Mean ± SEM; *P≤0.050). 
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4.2 MicroRNA and mRNA levels analysis between FG-2 and FG-2R cell lines 
 
 Since the miRNA levels were going to be analyzed using the comparative CT 
method, two miRNAs, RNU6B and RNU48, were quantified to determine which would be 
an adequate endogenous control in our study models. We observed that RNU6B presented 
less variation between the FG-2 and FG-2R cell samples than RNU48 (SEM (RNU6B) = 
1.09 vs SEM (RNU48) = 1.93) and also between our FG-2 and FG-2R medium samples 
(SEM (RNU6B) = 1.18 vs SEM (RNU48) = 1.37) (Figure 11). MRNA levels were also 
quantified using the comparative CT method and B2M was used as our endogenous control 
since previous results demonstrated that its expression was stable and constant among 
samples. 
 
 
 
 
Figure 11 - Comparison between intracellular and extracellular expression levels of RNU-6B and RNU-48 in 
FG-2 and FG-2R cell lines and respective medium (Mean ± SEM). 
 In figures 12 to 14, are represented the results relative to the intracellular and 
extracellular expression levels of miRNA-21 and miRNA-210 and intracellular levels of 
MNT and c-Myc in FG-2 and FG-2R cell lines. 
According to the results regarding miRNA-21, we observed a trend for higher 
intracellular levels of this miRNA in the FG-2R cell line at end of the second month of 
exposure to 10µM of erlotinib when compared with the FG-2 cell line (P= 0.185). However, 
we did not found statistical significant differences between the extracellular levels (P= 
0.319) (Figure 12). 
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Regarding miRNA-210, at the end of the FG-2R cell line establishment (2nd month 
of exposure to 10µM erlotinib) we observed not only a 6.26 fold-increase in miRNA-210 
intracellular levels (P= 0.009) but also a 19 fold-increase in miRNA-210 extracellular levels 
(P= 0.017) when compared with the FG-2 cell line (Figure 13). 
 
Figure 12 – miRNA-21 intracellular and extracellular levels fold change between FG-2 cell line and FG-2R 
cell line at three different stages of establishment (Mean ± SEM). 
Figure 13 - miRNA-210 intracellular and extracellular levels fold change between FG-2 cell line and FG-2R 
cell line at three different stages of establishment (Mean ± SEM, *P≤0.050). 
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According to the results obtained for mRNA MNT and c-Myc levels quantification, 
we observed a statistical significant decrease in the intracellular levels of both transcripts at 
the endpoint of the FG-2R cell line establishment when compared with the FG-2 cell line 
(P< 0.001 in both transcripts) (Figure 14). 
 
4.3 MicroRNA-210-dependent erlotinib resistance mechanism 
 
 Since miRNA-210 intracellular and extracellular levels were upregulated in the FG-
2R cell line when compared with the FG-2 cell line, miRNA-210 knockdown experiments 
were performed in the FG-2R cell line to verify its influence in erlotinib resistance.   
 According to the results obtained of the FG-2R cell line response to erlotinib after 
miRNA-210 inhibitor transfection, we observed a statistical significant decrease in the cell 
viability of the FG-2R cell line after miRNA-210 inhibitor transfection when compared with 
the FG-2R cell line transfected with a scramble sequence (P= 0.009) (Figure 15).  
Figure 14 – C-Myc and MNT intracellular levels fold change between FG-2 cell line and FG-2R cell line at 
three different stages of establishment (Mean ± SEM, *P≤0.050). 
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To verify if FG-2R erlotinib resistance mechanism was dependent on miRNA-210 
and MNT functional relationship and its possible effect on c-Myc-Max interaction in the cell 
cycle, different studies were performed. First, miRNA-210 and MNT functional relationship 
was evaluated through FG-2 cell line transfection with a miRNA-210 inhibitor. A statistical 
significant increase in MNT levels was observed in the FG-2 cell line transfected with a 
miRNA-210 inhibitor when compared with a control condition where the FG-2 cell line was 
transfected with a scramble sequence (P= 0.005) (Figure 16). 
Figure 15 – Comparison between the number of viable FG-2R cells transfected with a scrambled sequence or 
with a miRNA-210 inhibitor after 72h exposure to erlotinib (Mean ± SEM; *P≤0.050). 
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 Secondly, c-Myc-Max interaction in G1 phase of the cell cycle was evaluated on FG-
2, FG-2R and FG-2 transfected with a miRNA-210 inhibitor. According to the results, we 
observed an increase in c-Myc-Max interaction in FG-2R cell line when compared with FG-
2 cell line (1.76 ± 0.34) but not a significant difference in c-Myc-Max interaction when 
comparing FG-2 transfected with a miRNA-210 inhibitor and FG-2 cell line (1.08 ± 0.76) 
(Figure 17). 
 
 
 
 
 
 
  
FG-2 FG-2R 
FG-2       
(miRVana 
antimiR-210) 
c-Myc 
Max 
Figure 16 – MiRNA-210 and MNT intracellular levels fold change between FG-2 cell line transfected with a 
scramble sequence or with a miRNA-210 inhibitor (Mean ± SEM, *P≤0.050). 
 
Figure 17 – Evaluation of c-Myc-Max interaction in G1 phase of the cell cycle in FG-2, FG-2R and FG-2 
transfected with a miRNA-210 inhibitor. 
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4.4 FG-2 cell line conditioning 
 
 Experiments on the FG-2 cell line were also performed using FG-2R cell line 
conditioned medium to verify if any microRNA levels changes and phenotypical modulation 
occurred. According to the results, after 8h of exposure to FG-2R cell line conditioned 
medium no statistical significant differences were obtained in miRNA-21 and miRNA-210 
intracellular levels when comparing FG-2 cell line exposed to FG-2 conditioned medium or 
FG-2R conditioned medium (Figure 18). 
 
Figure 18 - MiRNA-21 and miRNA-210 intracellular levels fold change between FG-2 cell line exposed, 
during 8h, to FG-2 conditioned medium or FG-2R conditioned medium (Mean ± SEM). 
  
According to the results of a longer exposure time of the FG-2 cell line to FG-2R cell 
line conditioned medium, also no statistical significant differences were obtained in miRNA-
21 and miRNA-210 intracellular levels when comparing FG-2 and FG-2 exposed to FG-2R 
conditioned medium during different periods of time (Figure 19). 
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Figure 19 - MiRNA-21 and miRNA-210 intracellular levels fold change between FG-2 cell line and FG-2 cell 
line exposed to FG-2R conditioned medium during 2 days, 1 week or 2 weeks (Mean ± SEM). 
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5. Discussion 
 
ccRCC is a neoplasia that presents an aggressive phenotype and high potential to 
metastasize due to its intense vascularity and angiogenic factors upregulation [53, 70]. Once 
the main characteristics and dependencies of this tumor type started to be elucidated, an 
effort was made on the development of new targeted therapies. Bevacizumab, a monoclonal 
antibody that inhibits VEGF, was an important step towards a more specific treatment in 
mRCC patients due to the constant state of hypoxia and VEGF upregulation that exists in 
this tumor model [68-70, 104]. The VEGF sequester performed by bevacizumab, in vivo, 
leads not only to the inhibition of VEGF-VEGFR binding on endothelial cells, reducing 
tumor vessel formation but also could inhibit VEGF-VEGFR binding in tumor cells, 
reducing the autocrine VEGF/VEGFR signaling loop and consequent activation of 
MAPK/ERK and PI3K/AKT signaling pathways [105, 106]. According to our in vitro 
results, bevacizumab did not have an effect on cell viability of a ccRCC cell line. However, 
since the positive effect of bevacizumab in mRCC patients treatment has been proven, this 
result may indicate that its effect on ccRCC development and progression is mainly through 
tumor vessel formation inhibition, an endpoint that could not be analyzed through an in vitro 
study using a viability test [104]. Additionally, this data suggests that the autocrine 
VEGF/VEGFR signaling loop and consequent signaling pathways activation could not be 
relevant to cell survival and proliferation in ccRCC or are easily surpassed by signaling 
pathways activation through other receptors and mechanisms. In vitro bevacizumab 
treatment overcome in ccRCC cells may be consequence of EGFR activation and 
consequently MAPK/ERK and PI3K/AKT related signaling pathways activation [75]. EGFR 
overexpression and overactivation of downstream signaling cascades have been reported and 
confirmed at our group in ccRCC, revealing its importance [107-110]. Since erlotinib led to 
a decrease in FG-2 cells viability, this indicates the key role of EGFR and related signaling 
pathways have on cell survival and proliferation in ccRCC. Combination therapy has 
presented itself as crucial approach on treating cancer because of its potential to reduce 
resistance to targeted therapies and improve efficacy through the inhibition of multiple 
receptors [111]. The combination of erlotinib and bevacizumab may be beneficial on treating 
RCC since they target different receptors, namely EGFR and VEGFR, that share both 
parallel and reciprocal downstream signaling mechanisms, such as PI3K/AKT and 
MAPK/ERK [105]. In fact, our in vitro results showed the positive effect that the 
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combination of erlotinib and bevacizumab may have on treating ccRCC patients since cells 
treated with this combined approach showed lower proliferation rates. EGFR and VEGFR 
crosstalk can be associated with TGF-α, which is highly expressed in ccRCC due to HIF 
accumulation [69, 70]. This ligand has the ability of activating EGFR and, consequently, 
increase the production of VEGF in human cancer cells [69, 70, 105]. Associated with this 
mechanism are EGFR-related MAPK/ERK and PI3K/AKT signaling cascades activation 
and consequent migration of three different transcription factors, STAT3, Sp1 and HIF to 
the VEGF promoter region [112]. Additionally, it has been suggested that inhibition of 
EGFR-related signaling pathways by gefitinib leads to VEGF downregulation [113, 114]. 
Recent work has also demonstrated that inhibition of the downstream EGFR-mediated 
effector mTOR reduces VEGF expression and capillary tube formation by endothelial cells 
[115]. Interestingly, a study associated EGFR targeted therapy resistance with increased 
levels of VEGF which were associated with an increase in angiogenic potential in vitro and 
tumor angiogenesis in vivo [112]. All these findings highlight the EGFR and VEGFR 
crosstalk and the common downstream signaling pathways that can influence tumor 
development and progression revealing the importance of using them as therapeutic targets. 
Unfortunately, the use of erlotinib alone or simultaneously with bevacizumab did not exhibit 
a consistent effect on mRCC patient´s treatment in phase I/II clinical trials [83, 84]. One of 
the reasons behind these results may be associated with erlotinib toxicity. Since erlotinib 
doses exceeding 150mg/day produced severe side effects in mRCC patients, the necessity of 
adjusting erlotinib dosage may lead to a greater tumor cell survival and the ability of these 
cells to adapt and develop resistance mechanisms [83]. Further clinical trials should also be 
performed using erlotinib and bevacizumab in earlier stages of RCC to verify if the synergy 
of these two drugs is greater and if, ultimately, a better response to treatment occurs.  
MiRNAs may be a way to unveil targeted therapies resistance, allowing a better 
understanding of treatment response and also to perspective new therapeutic approaches. 
Different studies in different tumor models reported the overexpression and consequent 
involvement of miRNA-21 in EGFR targeted therapies resistance [42, 92, 93]. Since 
miRNA-21 targets PTEN, which negatively regulates AKT activity, its overexpression 
would lead to PTEN downregulation and consequent downstream activation of PI3K/AKT 
signaling pathway, surpassing the inhibitory effect of EGFR targeted therapies and leading 
to cell survival and proliferation [42]. According to our results, miRNA-21 does not seem to 
be involved in any resistance mechanism in an erlotinib-resistant RCC cell line. However, 
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on the other hand, miRNA-210 seems to be relevant to the erlotinib-resistant phenotype 
acquisitionsince it was overexpressed in an erlotinib-resistant RCC cell line, FG-2R, when 
compared with the parental RCC cell line, FG-2.  Upon miRNA-210 knockdown on the 
erlotinib-resistant RCC cell line, sensitivity to erlotinib was restored confirming the 
importance of this miRNA on erlotinib resistance development. This result could be 
important to understand why erlotinib alone or in combination with bevacizumab did not 
have any benefic effect on mRCC patient’s treatment [83, 84]. An overexpression of 
miRNA-210 was reported in RCC patients and higher levels of this miRNA were associated 
with higher tumor grades and metastasis [95]. Zhao and coworkers also showed that miRNA-
210 was overexpressed in serum samples of patients with RCC compared with healthy 
controls and at our group miRNA-210 plasma levels were also associated with greater tumor 
size and metastasis [116]. Taken together, high levels of miRNA-210 could be associated 
with the non-response to erlotinib by mRCC patients. Since miRNAs are present in most 
biologic fluids and are highly stable in circulation, mainly due to being released inside of 
exosomes, it is important to consider them as one of the top candidates for circulating 
biomarkers [33-35]. In fact, miRNA-210 could represent a good biomarker for erlotinib 
treatment response, after in vivo studies confirmed and validated our results, allowing a more 
precise and personalized treatment. Ultimately, a miRNA-210 inhibitor could be used in the 
future as adjuvant therapy to erlotinib when treating RCC patients since recent in vivo studies 
have been demonstrating the ability of miRNAs to influence cancer growth and progression. 
For example, Ohno and co-workers efficiently deliver, in vivo, let-7a, a miRNA that 
functions as a tumor suppressor, to breast cancer cells in RAG2–/– mice by loading it to 
modified exosomes [117, 118]. The modified exosomes had GE11 peptide, an EGFR 
agonist, in their membranes to specifically deliver exosomal content to EGFR-expressing 
breast cancer cells [117]. This treatment suppressed tumor growth and no major organ 
damage was detected in the injected mice. 
Our in vitro study also showed that combined with the increase of miRNA-210 levels, 
MNT mRNA (a miRNA-210 target) levels were downregulated in the erlotinib-resistant 
RCC cell line when compared with the parental RCC cell line [96]. The functional 
relationship of miRNA-210 and MNT was confirmed upon miRNA-210 knockdown in the 
RCC cell line, FG-2. MNT is a known antagonist of c-Myc, with a transcriptional repressor 
activity [101]. MNT and c-Myc compete for Max binding, an essential partner, mainly 
during the G1/S phase of the cell cycle inhibiting or promoting cell cycle entry and 
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progression, respectively [119]. On the one hand, c-Myc-Max heterodimers bind DNA and 
activate transcription of genes such as cyclins D1 and D2, cyclin E, CDK4 (cyclin-dependent 
kinase 4) and cyclin B1 [119, 120]. On the other hand, MNT-Max heterodimers also have 
the ability of DNA binding but with a transcriptional repressor activity [101]. Concomitantly 
with the upregulation of miRNA-210 levels and downregulation of MNT mRNA levels in 
the erlotinib-resistant RCC cell line, we verified an increase in c-Myc-Max interaction in the 
G1 phase of the cell cycle when compared with the parental RCC cell line. A greater c-Myc-
Max interaction surpasses, at some degree, erlotinib EGFR inhibition, since c-Myc is a 
transcription factor highly activated through EGFR-related pathways [103]. This complex 
has the ability to regulate the transcription of many genes associated with different cellular 
processes, and, when dysregulated leads to a loss of cell cycle control and proliferation, 
metabolism dysregulation and metastatic potential increase [121]. Unfortunately, upon 
miRNA-210 knockdown we could not obtained a consistent result regarding the expected 
decrease of c-Myc-Max interaction.  
Another interesting result was the presence of only the p22 Max isoform in the erlotinib-
resistant RCC cell line when compared with the presence of both p21 and p22 Max isoforms 
in the parental RCC cell line. Although not many studies have been developed on this subject 
and the specific function of these two Max isoforms is yet unclear, reports showed that p22 
Max isoform can form homodimers and silently bind DNA while p21 Max isoform can not 
[122]. Additionally, c-Myc-p22 Max heterodimer binds DNA slightly better than c-Myc–
p21 Max heterodimer [122]. Taking in consideration both facts, we verify that in the 
erlotinib-resistant RCC cell line we, not only have a greater c-Myc-Max interaction, but also 
this interaction is mainly between c-Myc-p22 Max isoform which has a superior ability of 
DNA binding and, ultimately could lead to a greater effect on gene expression and cell 
processes dysregulation. Moreover, the ability of p22 Max isoform to form homodimers and 
silently bind DNA could allow the erlotinib-resistant RCC cell line to regulate, at some level, 
all the dysregulated events generated from a greater c-Myc-Max interaction [122]. 
Regarding the conditioning of the RCC cell line, FG-2, with the erlotinib-resistant RCC 
cell line conditioned medium did not exhibit significant results. No intracellular miRNA-21 
and miRNA-210 levels changes were obtained in the FG-2 cell line in any of the exposure 
times to FG-2R conditioned medium and also no phenotypic alterations were observed. 
MiRNAs have been described as important mediators of intercellular communication since 
they are highly stable when in circulation and can modulate recipient cells, systemically [92, 
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123]. Their high stability and protection against ribonucleases is mainly due to the fact that 
miRNAs are packaged in lipid vesicles, exosomes, or associated with proteins, AGO2 
mostly, or even with lipoprotein complexes [123]. Recently, many studies have been 
focusing on cancer exosomes-mediated cell communication and the ability of these 
nanovesicles to transport miRNAs in their lumen, allowing them to interfere with different 
cellular processes in the recipient cells [37, 123, 124]. Regarding our results, exosomes 
containing microRNAs present in the conditioned medium possibly are not being 
internalized by the FG-2 cell line and no microRNAs levels changes occurs. Another 
possible justification is that although is fascinating the idea of miRNAs having an important 
role on tumor progression in a local and systemic manner, mainly due to being shuttled inside 
of exosomes, recent reports showed that miRNAs in circulation are mainly associated with 
AGO2 and, to a lesser extent, with other AGO proteins [125, 126]. However, how miRNAs-
AGO2 complexes are exported from the cell is not fully clarified but it has been proposed 
that these complexes are released by death or apoptotic cells and remain in the extracellular 
space because of the high stability of the AGO2 protein [123]. Associating these findings 
with our FG-2 cell line conditioning results, this may indicate that even with higher 
extracellular levels of miRNA-210 in the FG-2R cell line when compared with the FG-2 cell 
line, we could not obtain miRNA levels changes due to miRNAs being mainly associated 
with AGO2 and having no ability of modulating recipient cells on this manner. 
 In conclusion, miRNA-210 seems to be involved in an erlotinib resistance 
mechanism in RCC by influencing c-Myc-Max interaction and, ultimately, leading to cell 
cycle entry and cell proliferation. 
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6. Conclusion and Future Perspectives 
 
RCC represents the most lethal urologic neoplasia mainly due to the non-existence of a 
standard screening test for the early detection and also due to the lack of therapeutic options 
with a beneficial effect in advanced RCC treatment during a significant period of time.  
The use of targeted therapies to key molecules involved in RCC development has been 
revolutionizing cancer treatment. The combination of these therapies has allowed to surpass 
treatment limitations such as treatment resistance and improves efficacy through the 
inhibition of different signaling pathways. RCC is characterized by a constant state of 
hypoxia in non-hypoxic conditions due to VHL loss and consequent accumulation of HIF. 
This accumulation leads to upregulation of different genes such as VEGF and TGF-α, which 
ultimately induces VEGFR activation mainly on endothelial cells and consequent 
angiogenesis stimulation and tumor cells EGFR activation leading to cell proliferation and 
cell survival.  Ultimately, these findings suggest that VEGF and EGFR could represent good 
therapeutic targets in RCC. According to our in vitro results the combination of 
bevacizumab, a VEGF sequester, and erlotinib, an EGFR inhibitor, seem to have a greater 
effect on a RCC cell line treatment when compared with erlotinib or bevacizumab alone.  
However, clinical trials demonstrated that erlotinib alone or in combination with 
bevacizumab does not seem to represent a good therapeutic option in mRCC patients 
highlighting the need to study and evaluate potential treatment resistance mechanisms.  
MiRNAs may be a way to unveil targeted therapies resistance since they regulate gene 
expression of different proteins involved in crucial cellular processes. MiRNA-210, an HIF 
regulated miRNA, seems to be an important mediator of erlotinib resistance in RCC. 
Regarding our in vitro results, intracellular and extracellular miRNA-210 levels were 
upregulated in an erlotinib-resistant RCC cell and by targeting MNT seems to increase c-
Myc-Max interaction in the G1 phase of the cell cycle. C-myc-Max heterodimer is an 
important mediator of cell cycle entry and progression since it binds to DNA and increases 
the expression of certain genes such as cyclins and CDKs. Taken together these results, 
miRNA-210 may represent a good biomarker for treatment response allowing a more 
personalized RCC patient´s treatment and also be seen as potential adjuvant therapy to 
erlotinib using a delivery model that allows miRNA stability and tumor-specific action. 
Further studies should be performed in G1 phase of the cell cycle in the erlotinib-resistant 
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RCC cell line and the parental RCC cell line. First, miRNA-210 mediated resistance 
mechanism should be further validated and replicated using a miRNA-210 inhibitor. 
Moreover, MNT-Max interaction should also be evaluated in order to verify if the increase 
in the c-Myc-Max interaction in the erlotinib-resistant RCC cell line is concomitantly related 
with a decrease in MNT-Max interaction. Ultimately, an evaluation of protein expression of 
genes regulated by c-Myc-Max heterodimer should also be performed, to study if the 
increase in c-Myc-Max interaction in the erlotinib-resistant RCC cell line as a functional 
consequence.  
In vivo studies could also be performed to validate our findings and evaluate if miRNA-
210 could be used as a circulating biomarker in erlotinib treatment response in RCC patients, 
and even if a miRNA-210 inhibitor could be considered as adjuvant therapy when using 
erlotinib. 
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The ErbB/HER tyrosine kinase receptors family plays a key regulatory role in different 
cellular processes by activating several signaling pathways. In different tumor types, 
mutations or overexpression of the ErbB family members are a common feature, 
which led to the development of targeted therapies against this receptors. Although 
with this kind of treatment we are heading to a more personalized medicine, the 
development of acquired resistance is still an issue, therefore, several studies focused 
on discovering the mechanisms behind it. More recently, miRNAs have been described 
as important mediators of acquired resistance, specifically, acquired resistance to ErbB 
family targeted therapies. Ultimately, miRNA-based therapeutics using exosomes as a 
drug delivery model can revolutionize today’s approach of cancer treatment. 
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Background
miRNAs
miRNAs are a class of noncoding RNAs 
(19–25 nucleotides in length) that control 
gene expression by either degrading or block-
ing translation of mRNAs, a process that 
depends on the miRNA and the respective 
mRNA target degree of complementar-
ity [1]. miRNA biogenesis is a multiphase 
process which initiates at the nucleus with 
the transcription of a primary RNA, the 
pri-miRNA, by RNA polymerase II [2]. Fol-
lowing transcription, pri-miRNA is pro-
cessed by Drosha, a RNase III endonuclease, 
alongside with cofactor DGCR8, creating 
a pre-miRNA [3]. This precursor ultimately 
is exported to the cytoplasm by Exportin 5 
where is processed by another RNase, Dicer, 
leading to the production of a mature 22 base 
pairs miRNA duplex [2]. The mature miRNA 
enters the RNA-induced silencing complex 
(RISC), whose main components are TRBP, 
AGO1–4, GEMIN3 and GEMIN4 becom-
ing, ultimately, a functional miRNA [4]. 
This complex binds to the target mRNA at 
3′UTR region by complementarity leading 
to gene silencing [5].
A miRNA is not specific for a certain 
mRNA, it can regulate up to 100 different 
mRNAs and is also described that more than 
10,000 mRNAs seem to be regulated by 
miRNAs [6]. Thus, changes in the miRNA 
processing and expression patterns could be 
associated with different pathologies, includ-
ing cancer, suggesting that miRNAs are 
involved in many cellular function disorders, 
which includes carcinogenesis [7].
After the discovery of miRNA-15a and 
miRNA-16-1 as the first miRNAs with 
tumor suppressor functions in chronic lym-
phocytic leukemia in 2002, many miRNAs 
have been described as mediators of cancer-
related signaling pathways, regulating pro-
liferation, apoptosis, angiogenesis and even 
epithelial–mesenchymal transition (EMT), a 
key step for the metastatic process [8,9]. Since 
miRNAs are associated with different bio-
logical processes, they have been described 
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to act as oncogenes, tumor suppressors or even modu-
lators of cancer stem cells and metastasis formation. 
Oncomi RNAs are, usually, overexpressed in cancer 
since they are known to downregulate tumor suppres-
sor genes and tumor suppressor miRNAs are respon-
sible for downregulating oncogenes, so are mostly 
underexpressed in malign neoplasms [10,11]. However, 
this dichotomous approach may have its limitations. 
For example, miRNA-17 is associated, in B-cell lym-
phoma, with faster tumor development, while it can 
suppress cancer growth by downregulating AIB1 
expression in breast cancer [12,13]. Therefore, we have 
to take in consideration the fact that miRNAs may act 
in a tissue-specific manner such that a single miRNA 
can be either an oncomiRNA or a tumor suppressor 
miRNA.
Regarding the miRNAs role in cellular processes 
such as proliferation, apoptosis or angiogenesis, it is 
important to take into account the effect that changes 
in miRNA levels may have in treatment response, 
since targeted therapies are used for specific pro-
teins and  signal pathways related with this biological 
 processes [8,9].
Cancer treatment
Chemotherapy, along with surgery and radiotherapy, 
has been a crucial approach for cancer treatment. 
These different types of treatment can be used alone 
or in different combinations, and either simultane-
ously or sequentially. However, chemotherapy-/radio-
therapy-induced cell damage occurs preferentially 
but not exclusively in cancer cells, causing many side-
effects [14]. For this reason, nowadays, a big effort is 
being made in order to improve a personalized medi-
cine that focus on the discovery and development 
of molecular targeted drugs that take advantage of 
genetic addictions, dependencies and vulnerabilities of 
cancer cells. This type of methodology would be more 
specific than previous described approaches by mini-
mizing side effects on normal cells [15]. Additionally, 
different high-throughput technologies, still under 
development, like genome sequencing and various 
kinds of microarrays, will allow the knowledge of the 
genetic, epigenetic and proteomic background, from 
each individual and tumor, which ultimately will lead 
to a more personalized treatment [16].
The concept of targeting a pathogenic driver abnor-
mality using a small molecule was first validated in 
1988 by the successful treatment of patients with acute 
promyelocytic leukemia harboring translocations in 
the RARα gene with all-trans retinoic acid [17]. Addi-
tionally, the use of imatinib, a BCR-ABL inhibitor, as a 
chronic myeloid leukemia treatment in 1996, marked 
the era of the design of small therapeutic molecules 
applied in cancer treatment [18]. The 5-year estimated 
overall survival rate for patients with this malignancy, 
characterized by the BCR-ABL translocation, was 
89% when imatinib was used as initial therapy [19].
Even with all this development and improvement 
in cancer therapy, resistance to treatment still exists. 
Therapy failure is often due to development of drug 
resistance that may be inherent in a subpopulation of 
heterogeneous cancer cells or acquired subsequent to 
treatment [20]. A well-characterized resistance mecha-
nism is related with the activity of ABC transporters. 
ABC transporters are transmembrane proteins respon-
sible for the transport of a wide variety of substrates 
across cellular membranes, including hydrophobic 
drugs and antibiotic [21,22]. Overexpression of these 
proteins can be associated with reduced drug uptake, 
increased drug efflux and lead to lower drug efficacy 
and possibly to acquire drug resistance due to low drug 
levels in the cytoplasm [22]. The major members of the 
ABC transporters associated with multidrug resistance 
in cancer cells are ABCB1/MDR1, ABCCs (MRPs) 
and ABCG2 (BCRP/MXR/ABCP) [23]. However, 
several ABC transporters have been identified as trans-
porters of cancer chemotherapeutics agents, acquired 
chemotherapy drug resistance can occur at many lev-
els, modulated either by genetic or epigenetic factors. 
In fact, recent data demonstrate that the activity of 
certain miRNAs might be altered in order to achieve 
resistance to chemotherapy [24]. In the same line of 
thought, miRNAs can be as well linked to acquired 
resistance in molecular targeted therapy in several 
malignancy treatments. Latest evidences support this 
idea as it will be described next.
This review focus in the role of miRNAs as mediators 
of acquired resistance in ErbB family targeted therapies 
since this family plays a key regulatory role in nearly 
every aspect of cell biology. The ErbB/HER family 
contains four tyrosine kinase receptors, the epidermal 
growth factor receptor (EGFR/ErbB/Her1), Her2 (Neu, 
ErbB2), Her3 (ErbB3) and Her4 (ErbB4) [25]. Different 
factors as the identity of the ligand and oligomer com-
position of the receptor determine the specificity and 
potency of intracellular signals [26]. Downstream ErbB 
signaling includes phosphatidylinositol 3-kinase/Akt 
(PKB) pathway, the Ras/Raf/MEK/ERK 1/2 pathway 
and the phospholipase C (PLC-γ) pathway [27]. All of 
these pathways are interconnected and overlapping [26]. 
Overall, they regulate apoptosis, cell cycle progression, 
cytoskeletal rearrangement, differentiation, develop-
ment, immune response, nervous system function and 
transcription [28]. Mutations or increased expression 
of ErbB family members occur in several malignan-
cies [26,29]. For instance, ErbB1 overexpression occurs 
in head and neck, breast, bladder, prostate, kidney, 
10.2217/pgs-2016-0038www.futuremedicine.comfuture science group
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non-small-cell lung cancer (NSCLC) and glioma 
tumors, while mutations leading to a constitutively 
active receptor occur in glioma, lung, ovary and breast 
cancer. Overexpression of ErbB2 is frequent in breast, 
lung, pancreatic, colon, esophagus, endometrium and 
cervix cancer, whereas ErbB3 is overexpressed in oral 
squamous cell cancer [26,30].
Several targeted drugs have been developed against 
these protein kinases, however, cancers submitted to 
targeted therapy eventually become resistant [31,32]. 
miRNAs may be a way not only to unveil resistance 
mechanisms (Table 1) but also, if used as a treatment 
option, to overcome targeted therapy limitations.
miRNAs & targeted therapy resistance
ErbB targeted therapies resistance in cancer
Head & neck cancer
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth most common form of cancer worldwide 
with 650,000 new cases each year [45]. Palliative 
chemo therapy and the EGFR inhibitor, cetuximab, 
constitute the backbone of treatment for patients 
with HNSCC [46]. However, many patients with 
HNSCC tumors do not respond to EGFR-targeting 
 therapies [47].
Hatakeyama and coworkers demonstrated that one 
potential mechanism of acquired resistance to cetux-
imab in HNSCC involves the increased expression of 
HB-EGF that is regulated by miRNA-212. HB-EGF is 
known to bind both EGFR and HER4 and to induce 
EMT, enhance metastasis and modulate  chemot herapy 
resistance [48–50]. miRNA-212 showed a 27-fold 
decrease in 1Cc8 cetuximab-resistant cell line relative 
to SCC1 cetuximab-sensitive cell line. Expression lev-
els of HB-EGF and miRNA-212 were also examined 
in 32 additional HNSCC cell lines and keratinocyte 
cell line, demonstrating the inverse correlation of this 
two parameters. Increased expression of HB-EGF 
regulated by miRNA-212 and activation of receptor 
kinases other than EGFR, like HER3 and MET, and 
subsequent activation of AKT, were observed in 1Cc8 
cell line, and may play an important role in acquired 
resistance to cetuximab [33].
Lung cancer
Lung cancer is the leading cause of cancer related 
death worldwide [51]. Of all lung cancer cases, approxi-
mately 80–85% correspond to NSCLC [52]. One of 
the main issues regarding the therapeutic approach 
using chemotherapy or EGFR-tyrosine kinase inhibi-
tors (TKIs) in NSCLC is the acquired resistance that 
develops short after treatment [35,53]. In fact, the role 
of miRNAs, more specifically miRNA-21, has already 
been reported in NSCLC as a modulator of chemo-
therapy sensitivity [54]. Additionally, Shen et al. stated 
that this same miRNA correlated with PTEN levels 
(one of its most important targets) modulates gefitinib 
resistance in the same tumor model [55]. They ana-
Table 1. Summary of the miRNAs involved in the acquired resistance to ErbB family targeted 
therapies by cancer type.
Cancer Targeted Therapy miRNA involved Ref.
Head and neck cancer Cetuximab ↓ miRNA-212 [33]
Lung cancer Erlotinib ↑ miRNA-200 family [34]
 Gefitinib ↑ miRNA-21 [35]
  ↑ miRNA-30c, ↓ miRNA-103, ↓ miRNA-203, 
↑ miRNA-221 and ↑ miRNA-222
[36]
  ↑ miRNA-214 [37]
  ↑ miRNA-374a and ↓ miRNA-548b [38]
Gastric cancer Trastuzumab ↑ miRNA-21 [39]
Breast cancer Trastuzumab ↑ miRNA-21 [40]
  ↑ miRNA-221 [41]
  ↓ miRNA-375 [42]
 Lapatinib ↓ miRNA-630 [43]
 Neratinib   
 Afatinib   
Coloretal cancer Cetuximab ↓ miRNA-let7b, ↓ miRNA-let7e and 
↑ miRNA-17 
[44]
↑: Upregulation; ↓: Downregulation.
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lyzed the expression of miRNA-21 and PTEN protein 
in tumor tissues from NSCLC patients, comparing 
cancer tumor specimens with adjacent normal tis-
sues. A significantly higher expression of miRNA-21 
and a reduction in PTEN protein levels was found in 
tumor tissues, demonstrating a negative correlation. 
High miRNA-21/low PTEN expression levels indi-
cated a poor TKI clinical response and shorter over-
all survival in NSCLC patients. In order to test the 
effect of high miRNA-21/low PTEN expression on 
modulation of TKI sensitivity, a PC-9 TKI-sensitive 
cell line and a gefitinib-resistant cell line PC-9/GR 
were used. In vitro assays showed that miRNA-21 
was upregulated concomitantly to downregulation of 
PTEN in PC-9/GR cells. Moreover, overexpression of 
miRNA-21 significantly decreased gefitinib sensitiv-
ity by down-regulating PTEN expression and activat-
ing AKT and ERK pathways in PC-9 cells. Whereas, 
miRNA-21 knockdown dramatically restored gefi-
tinib sensitivity of PC-9/GR cells by up-regulation of 
PTEN expression and inactivation of AKT and ERK 
pathways, both in vivo and in vitro [56].
Another study performed by Izumchenko and 
coworkers demonstrated that TGFβ–miRNA200–
MIG6 pathway coordinates the EMT-associated 
kinase switch that induces resistance to EGFR inhibi-
tors [34]. They evaluated pairs of cancer cell lines with 
wild-type EGFR that were either sensitive (epithelial-
like) or resistant (mesenchymal-like) to erlotinib, 
an EGFR TKI. Treatment of erlotinib-sensitive cell 
lines with TGFβ resulted in complete EMT. Cells 
with induced mesenchymal phenotype, had both 
total EGFR and phospho-EGFR reduced and elevated 
expression of MIG6, acquiring a relative resistance 
to erlotinib, associated with a significant increase in 
AKT activity, due to higher levels of phospho IGFR, 
PDGFR, FGFR and FAK kinases [36,57]. Concurrently, 
expression levels of miRNA200 family decreased 
significantly. During TGFβ-mediated EMT, inhibi-
tion of the miRNAs 200 family results in upregu-
lated expression of the MIG6, a negative regulator 
of EGFR. The MIG6-mediated reduction of EGFR 
occurs concomitantly with a TGFβ-induced EMT-
associated kinase switch of tumor cells to an AKT-
activated EGFR-independent state. The expression 
levels MIG6 (mRNA)/miRNA200 ratio were inversely 
correlated with EMT and resistance to erlotinib, in 
both in vitro and in vivo models. Demon strating that 
TGF-β–miRNA200–MIG6 network orchestrates the 
EMT-associated kinase switch that induces resistance 
to EGFR inhibitors [34].
Studies in NSCLC also revealed an involvement of 
MET oncogene in TKIs resistance [37,58]. Garofalo and 
coworkers demonstrated that MET and EGFR-related 
miRNAs had a significant role in gefitinib resistance on 
NSCLC cell lines and in vivo models. NSCLC gefitinib-
resistant cell lines, Calu-1 and A549, did not revealed 
an expected miRNA-30b-c and miRNA-221/-222 
down-regulation and consequent increase in BIM and 
APAF-1 protein levels after treatment. miRNA-30b-c 
and miRNA-221/-222 knockdown increased gefitinib 
sensitivity in resistant and sensitive gefitinib cell lines 
indicating that these miRNAs are important modula-
tors of TKI resistance. Results from the same paper 
also show that MET overexpression controls gefitinib 
resistance through activation of the AKT/ERKs path-
way, mediated at least in part by the miRNA-103 and 
-203 downregulation since an induced expression of 
these miRNAs increases Calu-1 cells gefitinib sensi-
tivity. Additionally, Dicer knockdown reduced gefi-
tinib resistance and also migration and the expression 
of mesenchymal markers. Since miRNA-103 targets 
Dicer, these results may suggest that this miRNA could 
be involved in the EMT process through Dicer down-
regulation. Ultimately, all these results were supported 
by in vivo studies since miRNA-103 and miRNA-203 
overexpression or miRNA-221 and -30c knockdown 
resulted in tumor growth inhibition and increased 
 sensitivity to gefitinib in nude mice after treatment [59].
miRNA-214 has also been described as a gefitinib 
resistance mediator [60]. After exposure to increas-
ing concentrations of gefitinib, studies performed by 
Y-S Wang and coworkers in the resistant clone of a 
lung adenocarcinoma cell line, HCC827/GR, revealed 
an overexpression of miRNA-214. The upregulation 
of this miRNA leads to a PTEN down-regulation, 
which is involved in PI3K–AKT pathway [57]. PTEN 
protein dephosphorylates PI3K, that mediates activa-
tion of AKT, ultimately leading to an inactivation of 
this pathway [38]. So, miRNA-214 mediates gefitinib 
resistance in this model by activating PI3K/AKT path-
way, which has been described to confer resistance to 
EGFR-TKI by overcoming the EGFR blocking in pre-
vious studies [61]. Finally, miRNA-214 knockdown led 
to gefitinib sensitivity in HCC827/GR [60].
Additionally, other studies performed by Wang et al. 
also revealed a gefitinib resistance in NSCLC cell lines 
and in vivo models, but this time mediated by Axl-
altered miRNAs. Findings of the involvement of Axl 
kinase in acquired resistance to TKIs in this tumor 
model were prior to this article but Wang and his fellow 
workers proposed the involvement of the miRNA-374a 
and miRNA-548b in this resistance [62]. Analysis of 
the miRNA expression profile was performed in a gen-
erated gefitinib-resistant cell line, HCC827-Gef, in 
Calu1 cell line, which is resistant to TKI, and in tumor 
samples. Results revealed a relationship between Axl 
overexpression and the overexpression of miRNA-374a 
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and downregulation of miRNA-548b not only in the 
gefitinib-resistant cell lines but also in tumor samples. 
Knockdown of miRNA-374a and upregulation of 
miRNA-548b increased the sensitivity to gefitinib in 
gefitinib-resistant cell lines revealing their importance in 
this mechanism. Finally, results from the same authors 
also showed that miRNA-374a and miRNA-548b not 
only have a role in gefitinib sensitivity and gefitinib-
induced apoptosis but also essential roles in cell cycle 
arrest, EMT, migration and tumorigenesis of gefi-
tinib-resistant lung cancer cells in vitro and in vivo by 
 targeting WNT5A and CCNB1,  respectively [63].
Gastric cancer
Gastric cancer (GC) is the fourth most commonly diag-
nosed cancer and the second most common cause of 
cancer related death worldwide [39]. Results from a recent 
large-scale Phase III study demonstrated that trastu-
zumab combined with standard chemotherapy provided 
a significant survival advantaged compared with chemo-
therapy alone in advanced HER2-positive GC [64]. Even 
though trastuzumab can prolong the survival of patients 
with HER2-positive GC, most of them end up develop-
ing resistance, highlighting the importance in clarifying 
the mechanisms behind this event [65].
Eto and coworkers described that miRNA-21/PTEN 
pathway regulated the sensitivity of HER2-positive 
GC cell lines to trastuzumab through modulation of 
apoptosis. On one hand, they were able to demonstrate 
that overexpression of miRNA-21 not only downregu-
lated PTEN expression but also increased AKT phos-
phorylation, however, not affecting HER2 expres-
sion. On the other hand, suppression of miRNA-21 
increased PTEN expression and downregulated AKT 
phos phorylation, still not affecting HER2 expression. 
In addition, overexpression of miRNA-21 decreased 
GC cells sensitivity to trastuzumab by suppression of 
apoptosis; whereas suppression of miRNA-21 expres-
sion restored trastuzumab sensitivity of GC cells. 
These findings suggest that miRNA-21/PTEN path-
way may be crucial to trastuzumab acquired resistance 
mechanism in GC [66].
Breast cancer
Breast cancer remains the most frequently diagnosed 
malignancy and the primary cause of cancer-related 
death in women globally [51]. HER2 overexpression 
occurs in 10–34% of invasive breast cancers [41]. 
HER2-positive breast cancers are associated with 
more aggressive tumor phenotypes and often acquired 
resistance to therapy [67,68]. Additionally, the down-
regulation of key miRNA processing enzymes, such 
as  Drosha and Dicer, have been associated with the 
outcome, progression and recurrence of breast can-
cer. In fact, it was shown that Dicer is an indepen-
dent predictor of recurrence in the HER2-positive 
subtype [40,42,69]. Ye and coworkers showed that in 
a HER2-positive breast cancer cell line, SK-BR-3, 
miRNA-221 knockdown led to a significant decrease 
of surviving cells in the presence of trastuzumab, while 
overexpression of the pre-miRNA in question led to 
the opposite result. Trastuzumab resistance in this 
tumor model seems to be mediated by tumor suppres-
sor PTEN, since a miRNA-221  overexpression leads to 
a PTEN  downregulation [43,70].
The activation of IGF1R, an alternative growth fac-
tor receptor, represents a common feature of trastu-
zumab-refractory cells [71]. However, the underlying 
mechanism remained unclear until very recently, when 
Xing-Ming and coworkers demonstrated that epi-
genetic silencing of miRNA-375 induces trastuzumab 
resistance in HER2-positive breast cancer by targeting 
IGF1R [72]. Their findings revealed that miRNA-375 
targeted IGF1R and was downregulated in trastu-
zumab-resistant HER2-positive breast cancer cells. 
While overexpression of miRNA-375 restored trastu-
zumab sensitivity in cells, inhibition of miRNA-375 
induced trastuzumab resistance in HER2-positive 
breast cancer cells. They also showed that regulation 
of miRNA-375 expression was epigenetic since inhi-
bition of DNA methylation and histone deacetylation 
restored the expression of miRNA-375 in trastu-
zumab-resistant cells. Additionally, they found a nega-
tive correlation between the levels of miRNA-375 and 
IGF1R in breast cancer tissue samples. Lastly, epigen-
etic silencing of miRNA-375 causes IGF1R upregula-
tion, which at least partially explains the mechanism of 
trastuzumab resistance in breast cancer cells [72].
A similar work was performed by Gong et al. which 
consisted in in vitro experiments and in vivo analysis 
of HER2-positive breast cancers. HER2-positive-
trastuzumab-resistant cell lines were obtained by doing 
cell cultures in the presence of low-dose trastuzumab. 
miRNA analysis concluded that miRNA-21 was 
overexpressed in all resistant cell lines in comparison 
with parental ones. On one hand, knockdown of this 
miRNA resensitized the trastuzumab resistant breast 
cancer cells and its effects in proliferation and cell cycle. 
On the other hand, ectopic expression of miRNA-21 led 
to trastuzumab resistance in parental cell lines. Trastu-
zumab resistance mediated by miRNA-21 appears 
to be via tumor suppressor PTEN, since overexpres-
sion of this miRNA led to lower PTEN protein levels. 
Retrieving PTEN expression in resistant breast cancer 
cells restored trastuzumab activity, since this targeted 
therapy enhances PTEN phosphatase activity leading 
to AKT dephosphorylation [73]. In vivo studies were also 
performed and similar results were obtained leading to 
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Figure 1. Schematic representation of the miRNAs involved in ErbB targeted therapy acquired resistance and their targets in the 
multiple cell signaling pathways.
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the conclusion that miRNA-21 over expression in tumor 
xenografts results in resistance to trastuzumab by inhib-
iting PTEN expression. Finally, the clinical significance 
of these findings was evaluated by examining primary 
breast cancers from patients receiving trastuzumab 
therapy. miRNA-21 expression in breast cancer cells 
was reversely correlated with PTEN expression, and in 
line with a miRNA-21 upregulation, PTEN expression 
was lower in trastuzumab-resistant tumors [44].
Also, recent studies performed by Corcoran et al. 
in breast cancer cell lines revealed an involvement of 
miRNA-630 in resistance to HER-targeting drugs 
such as lapatinib, neratinib and afatinib [74]. Lapa-
tinib-resistant SKBR3 and HCC1954 cells and nera-
tinib-resistant HCC1954 cells showed a decrease in 
intra and extracellular levels of the miRNA-630 when 
compared with the parental cell lines. Transfection of 
miRNA-630 mimic to resistant cell lines enhanced the 
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Figure 2. Possible mechanisms of exosome-target cell interaction. (A) Interaction between exosomal membrane 
proteins and target cell receptors leads to intracellular signaling activation – juxtacrine fashion; (B) Interaction 
between an ectodomain, formed after protease cleavage of exosomal membrane proteins, and target cell 
receptors also leads to signaling pathways activation; (C) Fusion of the exosome with the recipient cell membrane 
and content release to the intracellular space in a nonselective manner.  
Adapted with permission from [75].
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antiproliferative effects of all the drugs in study. The 
miRNA-630 dependent resistance mechanism seems 
to be related, not only with the increase of IGF1R lev-
els, a target of miRNA-630, but also with the increase 
of EGFR and HER2 levels, targets of the drugs in 
study. The levels of the phosphorylated form of these 
proteins are also increased when miRNA-630 inhibi-
tion is performed in breast cancer cell lines. Finally, 
Corcoran et al. also proved that inhibition of the 
miRNA-630 in breast age-matched cancer cells was 
associated with increased motility, migration, invasion 
and resistance to anoikis [74].
Colorectal cancer
Colorectal cancer (CRC) is the third most common 
cancer worldwide and the fourth most common cause 
of death, affecting men and women almost equally [75]. 
The use of monoclonal antibodies against EGFR, such 
as cetuximab and panitumumab, are a common phar-
macologic approach in CRC treatment [76]. Besides the 
discovery that acquired KRAS mutations are a good 
predictive marker of cetuximab and panitumumab 
resistance in CRC, it is still unclear why certain 
patients respond to therapy and others do not [76,77].
Ragusa and coworkers made an expression pro-
file of 667 miRNAs in two human colorectal cancer 
cell lines, one cetuximab sensitive (Caco-2) and other 
cetuximab resistant (HCT-116). They identified a 
group of miRNAs differentially expressed and tested 
them in CRC patients. miRNAs let-7b and let-7e were 
downregulated in HCT-116 after cetuximab treatment, 
in which signaling downstream of KRAS remains 
activated. Let-7 family members are known to target 
KRAS, so their downregulation could be a mechanism 
that contributes to cetuximab resistance. Additionally, 
miRNA-17* (a CRC marker) is up- regulated in the resis-
tant-cell line and downregulated in the sensitive one, 
after cetuximab treatment [78]. Taken together, miRNA 
let-7b, let-7e and 17* could be considered as candidate 
 molecular markers of  cetuximab  resistance [79].
Regarding all this results, we observe that, in some 
cases, different miRNAs are involved in different 
acquired resistance mechanisms for the same drug and 
in the same tumor model. miRNAs are not specific for 
a single mRNA, moreover mRNAs and consequently 
proteins are not regulated by only one miRNA [6]. 
Additionally, signaling pathways related with ErbB 
family overlap [26]. With this being said, it is more 
likely that an acquired resistance to a targeted therapy 
would be mediated by a network of miRNAs rather 
than a single one, targeting multiple steps of different 
pathways (Figure 1). However, since miRNAs play a 
major role in targeted therapy resistance, more specifi-
cally, resistance to ErbB family targeted therapies, we 
could consider them as therapeutic options. The use of 
miRNAs mimics or inhibitors, when drug resistance is 
due to an under-expression or overexpression, respec-
tively, of the miRNA in question, should be consid-
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ered as adjuvant therapy to drugs such as cetuximab, 
 erlotinib, gefitinib and others.
The main issue regarding the use of miRNAs as 
therapeutic options is the specificity of the delivery 
in vivo. In other words, a direct delivery to the tumor, 
without affecting other body parts. Many studies have 
been made which led to huge improvements in this 
area and this introduces our next topic, exosomes.
Exosomes: a potential drug delivery model 
in EGFR-overexpressing tumors
Exosomes are membrane-bound vesicles of 40–100 nm 
in diameter present in almost all biological fluids [80]. 
They are released from most cell types, including 
cancer cells, into the extracellular space after fusion 
with the plasma membrane [81]. This type of extra-
cellular membrane vesicles are enriched in cholesterol, 
sphingo myelin and ceramide as well as lipid raft asso-
ciated proteins [81,82]. As a consequence of their origin, 
nearly all exosomes, independently of the cell type 
from which they originate, contain similar composi-
tion. However, the exosomal lumen, which is in part 
composed by mRNAs, miRNAs and other non coding 
RNAs is determined by the cell type which produced 
the exosomes [83]. In the last years, many authors 
reported differences in miRNA content when com-
paring exosomes from normal individuals with cancer 
patients [84,85]. Since exosomes are released and are able 
to circulate in most biological fluids, they can interact 
with neighboring or distant cells and ultimately lead 
to the modulation of the recipient cells [86]. There are 
three main possible mechanisms of intracellular com-
munication by exosomes. First, in a juxtacrine fashion, 
exosomal membrane proteins can interact with recep-
tors in a target cell and activate different signaling 
pathways. Second, proteases in the extracellular space 
can cleave exosomal membrane proteins, leading to a 
cleaved fragment-target cell surface receptor interac-
tion. This mechanism also activates intracellular sig-
naling. Finally, exosomes can fuse with the target cell 
membrane and release their contents, such as mRNAs 
and miRNAs, which can alter gene expression and pro-
tein translation of the recipient cell (Figure 2) [81]. The 
ability of exosomes to interact and modulate target 
cells and also their high stability in circulation makes 
them good candidates to in vivo delivery of differ-
ent molecules, such as miRNA mimics or inhibitors, 
which would allow us to surpass targeted therapies 
resistance mediated by miRNAs [87]. In fact, exosomes 
have already been used in in vivo models with differ-
ent purposes and in a wide-range of diseases [88]. More 
specifically, in cancer Phase I clinical trials, exosomes 
are being used to, either increase innate and adaptive 
immune responses against the tumor, or deliver thera-
peutic agents in a cancer-specific way [88]. Related with 
the exosomes high stability and ability of travelling in 
biological fluids, a Phase I clinical trial is investigating 
the ability of plant exosomes to deliver curcumin to 
normal and colon cancer tissue, since previous stud-
ies demonstrated that curcumin has a strong inhibi-
tory effect on the growth of colon cancer cell lines by 
 mediating signal transduction [89,90].
Regarding the focus of our review article, more 
recently, Ohno et al. showed that exosomes could 
be used as drug delivery carriers in an EGFR-over-
expressing cancer model. They used modified exo-
somes, with GE11 peptide in their membranes, to spe-
cifically deliver exosomal content to EGFR-expressing 
breast cancer cells. GE11 peptide binds to EGFR and 
is markedly less mitogenic than EGF. Also, in the same 
paper, efficient in vivo delivery of let-7a, a miRNA 
that functions as a tumor suppressor, was achieved 
by loading it to GE11+ exosomes and by injecting the 
modified exosomes intravenously in RAG2–/– mice, 
that were submitted, previously, to breast cancer cells 
transplantation [91]. This treatment suppressed tumor 
growth and no major organ damage was detected in 
the injected mice [92].
Although an exosome-based drug delivery model 
seems promising, many challenges still rise and 
have to be overcome. One of the main issues is the 
in existence of a standard technique to isolate and 
purify exosomes. Usually, ultracentrifugation is used 
to obtain exosomes, however this technique has some 
limitations since it leads to low production yield and 
contamination with protein aggregates and cellular 
debris, which may affect the quality of these nano-
vesicles [93]. Another issue is the lack of biochemically 
well-characterized exosomes and the fact that the exo-
some protein content varies depending on the cells that 
produced them [83,93]. These facts could determine the 
safety and effectiveness of an exosome-based treatment 
since certain molecules, such as MHC class I or II, 
could trigger a host immune response and eliminate 
these vesicles. Finally, the method of drug loading to 
exosomes should be optimized since the efficiency is 
relatively low [93]. Once these issues are surpassed, exo-
somes could become a novel therapeutic approach not 
only in cancer but in many other diseases allowing a 
more specific and potent drug effect.
Conclusion
miRNAs are an important epigenetic mechanism of 
acquired resistance to targeted therapies by cancer 
cells. Despite great findings lately, this subject still 
needs further research in order to completely under-
stand the mechanisms underlying acquired resistance 
of different drugs in a wider range of tumor types. 
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Executive summary
miRNAs
•	 miRNAs are a class of noncoding RNAs that control gene expression by either degrading or blocking 
translation of mRNAs.
•	 A miRNA is not specific for a certain mRNA, it can regulate up to 100 different mRNAs and is also described 
that more than 10,000 mRNAs seem to be regulated by miRNAs.
•	 Changes in miRNA levels may have an effect in treatment response, since targeted therapies are used for 
specific proteins and signal pathways related with biological processes, which are regulated by miRNAs.
Cancer treatment
•	 Chemotherapy and radiotherapy target, but not exclusively, cancer cells, causing several side-effects. Target 
therapy emerged in order to minimize those side-effects.
•	 Despite all the latest developments and improvements in cancer therapy, resistance to treatment still exists.
•	 Acquired chemotherapy drug resistance can be modulated by genetic and/or epigenetic factors. In fact, 
recent data demonstrate that certain miRNAs activity might be altered in order to achieve chemotherapy 
resistance.
•	 The ErbB/HER receptors family regulate apoptosis, cell cycle progression, cytoskeletal rearrangement and 
many other biological processes. Mutations or increased expression of ErbB family members occur in several 
malignancies, thus different ErbB/HER targeted therapies have been developed against this family of receptors.
•	 miRNAs may be a way not only to unveil resistance mechanisms but also, if used as a treatment option, to 
overcome targeted therapy limitations.
miRNAs & targeted therapy resistance
•	 One potential mechanism of acquired resistance to cetuximab in head and neck squamous cell carcinoma 
involves the increased expression of HB-EGF due to a decrease in miRNA-212 expression. HB-EGF promotes 
cetuximab resistance since it activates receptor kinases other than EGFR, like HER3 and MET.
•	 High expression levels of miRNA-21 are associated with gefitinib resistance in non-small-cell lung cancer 
(NSCLC) cell lines and also with trastuzumab resistance in HER2 positive gastric and breast cancer cell lines. 
The upregulation of this miRNA leads to a PTEN downregulation, which is involved in PI3K-AKT pathway. 
PTEN protein dephosphorylates PI3K that mediates activation of AKT, ultimately leading to AKT pathway 
inactivation.
•	 miRNA-214 and miRNA-221 overexpression are associated with gefitinib resistance in a lung adenocarcinoma 
cell line and trastuzumab resistance in a breast cancer cell line, respectively. Since PTEN is a target of these 
miRNAs, the resistance mechanism is also based in a PI3K/AKT pathway activation.
•	 In different lung cancer cell lines it has been demonstrated that TGF-β–miRNA200–MIG6 pathway coordinates 
the EMT-associated kinase switch that induces resistance to erlotinib.
•	 Garofalo and coworkers demonstrated that changes in MET and EGFR-related miRNAs levels, more specifically, 
miRNA-30c, miRNA-103, miRNA-203, miRNA-221 and miRNA-222 levels, had a significant role in gefitinib 
resistance on NSCLC cell lines and in vivo models.
•	 The overexpression of miRNA-374a and the downregulation of miRNA-548b have been correlated with Axl 
kinase overexpression that is involved in acquired resistance to gefitinib in NSCLC.
•	 miRNA-375 downregulation by epigenetic silencing causes IGF1R upregulation, which leads to trastuzumab 
resistance in HER2-positive breast cancer.
•	 In breast cancer cell lines, miRNA-630 downregulation is associated with resistance to HER-targeting drugs 
such as lapatinib, neratinib and afatinib. The miRNA-630 dependent resistance mechanism seems to be 
related, not only with the increase of IGF1R levels, a target of miRNA-630, but also with the increase of EGFR 
and HER2 levels, targets of the drugs in study.
•	 Let-7 family members are known to target KRAS, so let-7b and let7-e downregulation could be a mechanism 
that contributes to cetuximab resistance in colorectal cancer.
Exosomes: a potential drug delivery model in EGFR-overexpressing tumors
•	 Exosomes are membrane-bound vesicles released from most cell types, including cancer cells.
•	 The exosomal lumen, which is in part composed by mRNAs, miRNAs and other noncoding RNAs is determined 
by the cell type which produced the exosomes.
•	 Exosomes can interact with surroundings or distant cells and ultimately lead to the modulation of the 
recipient cells, since they are able to circulate in most biological fluids.
•	 The ability of exosomes to interact and modulate target cells and also their high stability in circulation makes 
them good candidates to in vivo delivery of different molecules, such as miRNA mimics or inhibitors.
•	 In Phase I clinical trials, exosomes are being used to, either increase innate and adaptive immune responses 
against the tumor, or deliver therapeutic agents in a cancer-specific way.
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Ultimately, these findings would allow a better under-
standing of tumor biology and therapy response, 
enforcing the development of a treatment even more 
personalized and efficient. In this review, we have 
highlighted miRNAs and their role in the develop-
ment of acquired resistance to ErbB family targeted 
 therapies in  different cancer models.
Future perspective
In the future, miRNAs could be used as biomarkers 
for treatment response, through an expression profile, 
and also as therapeutic options. Modified exosomes 
carrying antitumor miRNAs are a promising drug 
 delivery model that can revolutionize today’s approach 
of  cancer treatment.
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